U.S. patent application number 10/059920 was filed with the patent office on 2002-08-08 for method for diagnosing a vascular condition.
Invention is credited to Adams, Michael A., Graham, Charles H., Heaton, Jeremy P.W..
Application Number | 20020106634 10/059920 |
Document ID | / |
Family ID | 22180550 |
Filed Date | 2002-08-08 |
United States Patent
Application |
20020106634 |
Kind Code |
A1 |
Adams, Michael A. ; et
al. |
August 8, 2002 |
Method for diagnosing a vascular condition
Abstract
A method for diagnosing hypoxia, endothelial dysfunction, a
vascular or circulatory condition of a subject, in which the level
of expression of a gene, and/or the level of a metabolite or
metabolic by-product in a biological test sample is measured and
compared to a control sample so as to assess the vascular condition
of the subject, is described.
Inventors: |
Adams, Michael A.;
(Kingston, CA) ; Heaton, Jeremy P.W.; (Gananoque,
CA) ; Graham, Charles H.; (Kingston, CA) |
Correspondence
Address: |
Licata & Tyrrell P.C.
66 East Main Street
Marlton
NJ
08053
US
|
Family ID: |
22180550 |
Appl. No.: |
10/059920 |
Filed: |
January 29, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10059920 |
Jan 29, 2002 |
|
|
|
09302554 |
Apr 30, 1999 |
|
|
|
60083763 |
May 1, 1998 |
|
|
|
Current U.S.
Class: |
435/4 ; 435/6.16;
702/19; 702/20 |
Current CPC
Class: |
C12Q 1/6883 20130101;
C12Q 1/6886 20130101; C12Q 2600/158 20130101 |
Class at
Publication: |
435/4 ; 435/6;
702/20; 702/19 |
International
Class: |
C12Q 001/00; C12Q
001/68; G06F 019/00; G01N 033/48; G01N 033/50 |
Claims
What is claimed is:
1. A method for diagnosing a vascular condition in an individual,
comprising the steps of: iii) measuring the quantity of a RTP/Drg1
gene product in at least one biological sample obtained from said
individual; and iv) comparing the measured quantity of said
RTP/Drg1 gene product to a standard value for the quantity of
RTP/Drg1 gene product in a normal biological sample; wherein an
increase in the measured quantity of said RTP/Drg1 gene product
relative to the standard value is indicative of said vascular
condition.
2. The method of claim 1 wherein said standard value is a measured
quantity of said RTP/Drg1 gene product in a different biological
sample, said different biological sample being substantially
unaffected by a vascular condition associated with a reduction in
blood flow.
3. The method of claim 2 wherein said the biological sample and
said different biological sample are obtained from the same
individual.
4. The method of claim 3 wherein said different biological sample
is obtained prior to the onset of said vascular condition.
5. The method of claim 1 wherein said standard value is obtained
from a data bank.
6. The method of claim 1 wherein said vascular condition is
selected from the group consisting of peripheral vascular disease,
cancer, preeclampsia, renal failure, erectile dysfunction, abnormal
pregnancy, heart disease and stroke.
7. The method of claim 1 wherein said gene product is RNA.
8. The method of claim 1 wherein said gene product is a polypeptide
or an antibody binding fragment thereof.
9. The method of claim 1 wherein said biological sample is selected
from the group consisting of leukocytes, blood, serum, plasma,
saliva, urine and tissue.
10. A method for detecting hypoxia of endothelial dysfunction in an
individual, comprising the steps of: i) measuring the quantity of a
RTP/Drg1 gene product in at least one biological sample obtained
from said individual; and ii) comparing the measured quantity of
said RTP/Drg1 gene product to a standard value for the quantity of
RTP/Drg1 gene product in a normal biological sample; wherein an
increase in the measured quantity of said RTP/Drg1 gene product
relative to the standard value is indicative of hypoxia or
endothelial dysfunction.
11. The method of claim 10 wherein said standard value is a
measured quantity of said RTP/Drg1 gene product in a different
biological sample, said different biological sample being
substantially unaffected by hypoxia or endothelial dysfunction.
12. The method of claim 11 wherein said the biological sample and
said different biological sample are obtained from the same
individual.
13. The method of claim 12 wherein said different biological sample
is obtained prior to the onset of hypoxia or endothelial
dysfunction.
14. The method of claim 10 wherein said standard value is obtained
from a data bank.
15. The method of claim 10 wherein said gene product is RNA.
16. The method of claim 10 wherein said gene product is a
polypeptide or an antibody binding fragment thereof.
17. The method of claim 10 wherein said biological sample is
selected from the group consisting of leukocytes, blood, serum,
plasma, saliva, urine and tissue.
18. A method for detecting hypoxia or endothelial dysfunction in an
individual, comprising the steps of: i) measuring the quantity of a
PAI-1 gene product in at least one biological sample obtained from
said individual; and ii) comparing the measured quantity of said
PAI-1 gene product to a standard value for the quantity of PAI-1
gene product in a normal biological sample; wherein an increase in
the measured quantity of said PAI-1 gene product relative to the
standard value is indicative of hypoxia or endothelial
dysfunction.
19. The method of claim 18 wherein said standard value is a
measured quantity of said PAI-1 gene product in a different
biological sample, said different biological sample being
substantially unaffected by hypoxia or endothelial dysfunction.
20. The method of claim 19 wherein said the biological sample and
said different biological sample are obtained from the same
individual.
21. The method of claim 20 wherein said different biological sample
is obtained prior to the onset of said hypoxia or endothelial
dysfunction.
22. The method of claim 18 wherein said standard value is obtained
from a data bank.
23. The method of claim 18 wherein said gene product is RNA.
24. The method of claim 18 wherein said gene product is a
polypeptide or an antibody binding fragment thereof.
25. The method of claim 18 wherein said biological sample is
selected from the group consisting of leukocytes, blood, serum,
plasma, saliva, urine and tissue.
26. A method for detecting hypoxia or endothelial dysfunction in an
individual, comprising the steps of: i) measuring the quantity of a
uPAR gene product in at least one biological sample obtained from
said individual; and ii) comparing the measured quantity of said
uPAR gene product to a standard value for the quantity of uPAR gene
product in a normal biological sample; wherein an increase in the
measured quantity of said uPAR gene product relative to the
standard value is indicative of hypoxia or endothelial
dysfunction.
27. The method of claim 26 wherein said standard value is a
measured quantity of said uPAR gene product in a different
biological sample, said different biological sample being
substantially unaffected by hypoxia or endothelial dysfunction.
28. The method of claim 17 wherein said the biological sample and
said different biological sample are obtained from the same
individual.
29. The method of claim 28 wherein said different biological sample
is obtained prior to the onset of hypoxia or endothelial
dysfunction.
30. The method of claim 26 wherein said standard value is obtained
from a data bank.
31. The method of claim 26 wherein said gene product is RNA.
32. The method of claim 26 wherein said gene product is a
polypeptide or an antibody binding fragment thereof.
33. The method of claim 26 wherein said biological sample is
selected from the group consisting of leukocytes, blood, serum,
plasma, saliva, urine and tissue.
34. A method for detecting hypoxia or endothelial dysfunction in an
individual, comprising the steps of: i) measuring the quantity of
an arginine metabolite in at least one biological sample obtained
from said individual; and ii) comparing the measured quantity of
said arginine metabolite to a standard value for the quantity of
said arginine metabolite in a normal biological sample; wherein an
increase in the measured quantity of said arginine metabolite
relative to the standard value is indicative of hypoxia or
endothelial dysfunction.
35. The method of claim 28 wherein said arginine metabolite is ADMA
or L-NMMA.
36. A method of assessing an individual's risk for a vascular
condition comprising the steps of: i) measuring the quantity of a
RTP/Drg1 gene product in at least one biological sample obtained
from said individual; and ii) comparing the measured quantity of
said RTP/Drg1 gene product to a standard value for the quantity of
RTP/Drg1 gene product in a normal biological sample; wherein an
increase in the measured quantity of said RTP/Drg1 gene product
relative to the standard value is indicative of risk for said
vascular condition, and said risk correlates with the degree to
which said RTP/Drg1 gene product is elevated.
37. A method for detecting hypoxia or endothelial dysfunction in an
individual, comprising the steps of: i) isolating cells from said
individual; ii) measuring the invasiveness or of said cells in an
in vitro cellular invasion assay; and iii) comparing the measured
value to a standard value for said cells; wherein an increase in
invasiveness relative to said standard is indicative of hypoxia or
endothelial dysfunction.
38. A method for assessing an individual's risk for metastasis,
comprising the steps of: i) isolating cells from said individual;
ii) measuring the invasiveness of said cells in an in vitro
cellular invasion assay; and iii) comparing the measured value to a
standard value for said cells; wherein an increase in invasiveness
relative to said standard is indicative of an increased risk for
metastasis.
39. A method for assessing an individual's risk for metastasis,
comprising the steps of: i) measuring the quantity of at least one
substance in at least one biological sample obtained from said
individual; and ii) comparing the measured quantity of said
substance to a standard value for the quantity of said substance in
a normal biological sample; wherein an increase in the measured
quantity of said substance relative to the standard value is
indicative of an increased risk for metastasis.
40. The method of claim 39 wherein said substance is selected from
the group consisting of a RTP/Drg1 gene product, a uPAR gene
product, a PAI-1 gene product and an arginine metabolite.
41. The method of claim 40 wherein said biological sample consists
of non-cancerous cells.
42. A method for diagnosing a vascular condition in an individual,
comprising the step of: i) detecting at least one endocrine
disrupter in at least one biological sample obtained from said
individual; wherein the presence of said endocrine disrupter is
indicative of said vascular condition.
43. The method of claim 42 wherein said endocrine disrupter is
p,p-DDE.
44. The method of claim 43 wherein said vascular condition is
erectile dysfunction.
45. A method for assessing an individual's risk for contracting a
vascular condition, comprising the steps of: i) measuring the
quantity of at least one endocrine disrupter in at least one
biological sample obtained from said individual; ii) measuring the
quantity of an endogenous hormone in said biological sample; and
iii) determining the ratio of said disrupter to said endogenous
hormone in said biological sample; wherein the risk is proportional
to said ratio.
46. The method of claim 45 wherein said endocrine disrupter is
p,p-DDE and said endogenous hormone is testosterone.
47. The method of claim 46 wherein said vascular disorder is
erectile dysfunction.
48. A method of diagnosing a vascular condition in an individual,
comprising the steps of: i) measuring the quantity of at least two
substances chosen from the group consisting of a product of the
RTP/Drg1 gene, a product of the uPAR gene, a product of the PAI-1
gene and a product of abnormal arginine metabolism, in at least one
biological sample obtained from said individual; and ii) comparing
the measured quantity of said substances to a standard value for
the quantity of said substances in a normal biological sample;
wherein an increase in the measured quantity of at least one of
said substances relative to the standard value is indicative of
said vascular condition.
49. The method of claim 48 further comprising i) isolating cells
from said individual; ii) measuring the invasiveness of said cells
in an in vitro cellular invasion assay; and iii) comparing the
measured value to a standard value for said cells; wherein an
increase in invasiveness or an increase in the measured quantity of
at least one of said substances relative to the standard value is
indicative of said vascular condition.
50. A method of diagnosing hypoxia or endothelial dysfunction in an
individual, comprising the steps of: i) measuring the quantity of
at least two substances chosen from the group consisting of a
product of the RTP/Drg1 gene, a product of the uPAR gene, a product
of the PAI-1 gene and a product of abnormal arginine metabolism, in
at least one biological sample obtained from said individual; and
ii) comparing the measured quantity of said substances to a
standard value for the quantity of said substances in a normal
biological sample; wherein an increase in the measured quantity of
at least one of said substances relative to the standard value is
indicative of said hypoxia or endothelial dysfunction.
Description
RELATED APPLICATION
[0001] This application claims the benefit of Provisional
Application No. 60/083,763, filed May 1, 1998, the entire teachings
of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Many pathological conditions such as preeclampsia,
peripheral vascular disease, erectile dysfunction, cancers, renal
failure, heart disease, and stroke are often associated with
alterations in the normal vascular condition of the affected
tissues and/or systems. While the change from normal vascular
condition may arise through natural physiological processes, it may
also be induced transiently by perturbations such as surgical
procedures, and by the presence of exogenous agents within the
body. The change in vascular condition can result in a reduction in
blood flow to the associated organ or system, rendering that organ
or system hypoxic.
SUMMARY OF THE INVENTION
[0003] This invention relates to methods for diagnosing vascular
conditions, and to methods for detecting hypoxia or endothelial
dysfunction in an individual. In one aspect, the invention relates
to a method for diagnosing a vascular condition leading to a
hypoxic state. The methods of the invention comprise the steps
of:
[0004] i) measuring the level of at least one substance in at least
one biological sample, said substance having a level which is
affected by a vascular condition associated with a reduction in
blood flow, hypoxia or endothelial dysfunction; and
[0005] ii) comparing the level of the substance in said biological
sample with a standard to determine the extent of said vascular
condition associated with a reduction in blood flow, hypoxia or
endothelial dysfunction.
[0006] According to a further aspect of the method of the
invention, a corresponding measure of the level of at least one
substance is performed in at least one different biological sample,
said different biological sample being unaffected by a vascular
condition associated with a reduction in blood flow, hypoxia or
endothelial dysfunction. The substance may be selected from the
group consisting of genes, gene products, metabolites, metabolic
by-products, hormones, and exogenous agents.
[0007] In a particular embodiment, the invention is a method of
diagnosing a vascular condition associated with a reduction in the
flow of blood within an anatomical site of an individual and the
substance measured is a product of the RTP/Drg1 gene.
[0008] In additional embodiments, the invention is a method of
detecting hypoxia or endothelial dysfunction in an individual and
the substance measured is a product of a gene selected from the
group consisting of RTP/Drg1, uPAR and PAI-1. In another
embodiment, the invention is a method of detecting hypoxia or
endothelial dysfunction in an individual and the substance measured
is an arginine metabolite, such as L-NMMA or ADMA.
[0009] In another embodiment, the invention is a method of
diagnosing a vascular condition in an individual, comprising the
steps of:
[0010] i) measuring the quantity of at least two substances chosen
from the group consisting of a product of the RTP/Grp1 gene, a
product of the uPAR gene, a product of the PAI-1 gene and an
arginine metabolite, in at least one biological sample obtained
from said individual; and
[0011] ii) comparing the measured quantity of said substances to a
standard value for the quantity of said substances in a normal
biological sample; wherein an increase in the measured quantity of
at least one of said substances relative to the standard value is
indicative of said vascular condition. The method of this
embodiment can further comprise an indirect assay, such as
evaluating the in vitro invasiveness of cells isolated from said
individual.
[0012] In a further embodiment, the invention is a method of
assessing an individual's risk for a vascular condition associated
with a reduction in the flow of blood, comprising
[0013] i) measuring the quantity of a product of the RTP/Drg1 gene
in at least one biological sample; and
[0014] ii) comparing the quantity of said product of the RTP/Drg1
gene in said biological sample with a standard; wherein
[0015] an increase in the measured quantity of said RTP/Drg1 gene
product relative to the standard value is indicative of risk for
said vascular condition, and said risk correlates with the degree
to which said RTP/Drg1 gene product is elevated.
[0016] The invention also relates to a method of diagnosing a
vascular condition in an individual. The method comprises detecting
at least one endocrine disrupter in at least one biological sample
obtained from an individual, wherein the presence of said endocrine
disrupter is indicative of said vascular condition. In one
embodiment, the endocrine disrupter p,p-DDE is detected to diagnose
erectile dysfunction.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 is a representative autoradiogram obtained by
differential display analysis of cDNA fragments generated using RNA
extracted from MDA-MB-231 cells cultured under 1% or 20% oxygen.
The anchor primers dT.sub.11A, dT.sub.11C, and dT.sub.11G were
used, and are as indicated in the Exemplification. The band
representing RTP/Drg1 is shown by an arrowhead. Only bands
displaying differential intensity in at least three separate
independent experiments were excised, re-amplified, and
sequenced.
[0018] FIG. 2A is a Northern blot showing that culture of
HTR-8/SVneo first trimester trophoblasts, human aortic smooth
muscle cells (HASMC), as well as MCF10A1T3B and MDA-MB-231 breast
carcinoma cells for 24 h under 1% oxygen resulted in marked
increases in the 3-kb RTP/Drg1 transcript levels, compared with
culture under standard conditions (20% oxygen). Ethidium bromide
staining of 18S rRNA was used to indicate the relative amount of
RNA loaded in each lane. The experiments shown in this figure were
repeated at least twice and similar results were obtained each
time.
[0019] FIG. 2B is a Northern blot showing the time-course of
hypoxia induced RTP/Drg1 transcript expression in MDA-MB-231 cells.
Maximal mRNA levels were reached at 24 h of hypoxic culture and
they remained high thereafter. Ethidium bromide staining of 18S
rRNA was used to indicate the relative amount of RNA loaded in each
lane. The experiments shown in this figure were repeated at least
twice and similar results were obtained each time.
[0020] FIG. 2C is a Northern blot showing that reoxygination
suppressed expression of RTP/Drg1 transcripts. After a 24-h
incubation under 1% oxygen, cultures of MDA-MB-231 cells were
placed in a standard incubator at 20% oxygen to determine the
effect of reoxygenation on RTP/Drg1 mRNA levels. Transcript levels
were markedly reduced after 2 h of re-exposure to higher PO.sub.2
values and returned to near-control amounts by 6 h. Ethidium
bromide staining of 18S rRNA was used to indicate the relative
amount of RNA loaded in each lane. The experiments shown in this
figure were repeated at least twice and similar results were
obtained each time.
[0021] FIG. 2D is a Northern blot showing marked increases in
RTP/Drg1 mRNA levels in MDA-MB-231 cells cultured under 1% and 2%
oxygen but not in cells cultured under 4%, 10%, or 20% oxygen.
Ethidium bromide staining of 18S rRNA was used to indicate the
relative amount of RNA loaded in each lane. The experiments shown
in this figure were repeated at least twice and similar results
were obtained each time. The data in this figure are representative
of two or more independent experiments showing similar results.
[0022] FIG. 3A is a Western blot showing that MDA-MB-23 cells
displayed peak levels of the 43-kDa protein when cultured under
hypoxia for 16-24 h, and that the level of 43-kDa protein remained
high thereafter. The data in this figure are representative of two
or more independent experiments showing similar results.
[0023] FIG. 3B is a Western blot showing that culture of MDA-MB-23
cells under 4% oxygen resulted in increased expression of the
43-kDa protein, the highest levels of the 43-kDa protein were
observed in cells cultured under either 2% or 1% oxygen, in a
manner similar to that observed for RTP/Drg1 mRNA levels (FIG. 2D).
The data in this figure are representative of two or more
independent experiments showing similar results.
[0024] FIG. 3C is a Western blot showing that RTP/Drg1 protein
levels in MDA-MB-23 cells remained high even 48 h after return of
the cultures to 20% oxygen. The data in this figure are
representative of two or more independent experiments showing
similar results.
[0025] FIG. 4A is a Western blot showing the effect of cobalt
chloride, Tiron, and desferrioxamine mesylate (DFO) on the levels
of RTP/Drg1 protein in MDA-MB-231 cells. Culture for up to 72 h,
under 20% oxygen, in the presence of these compounds resulted in
time-dependent increases in RTP/Drg1 protein. In a manner similar
to hypoxic cultures, peak protein levels were observed after 24 h
of culture. The data in this figure are representative of three
independent experiments exhibiting similar results.
[0026] FIG. 4B is a Western blot showing the effect of cobalt
chloride, Tiron, and desferrioxamine mesylate (DFO) on the levels
of RTP/Drg1 mRNA in MDA-MB-231 cells. Culture for up to 72 h, under
20% oxygen, in the presence of these compounds resulted in
time-dependent increases in RTP/Drg1 mRNA. In a manner similar to
hypoxic cultures, peak mRNA levels were observed after 24 h of
culture. The data in this figure are representative of three
independent experiments exhibiting similar results.
[0027] FIG. 5A is a Northern Blot showing the effect of carbon
monoxide (CO) on the hypoxic up-regulation of RTP/Drg1 expression.
In contrast to cultures incubated under standard conditions (20%
oxygen), culture of MDA-MB-231 cells under 1% oxygen for 24 h
resulted in increased RTP/Drg1 mRNA. This up-regulation was
inhibited in parallel cultures by inclusion of 30% CO in the
hypoxic atmosphere, which resulted in a substantial decrease in
mRNA levels (third lane). In contrast, CO was unable to inhibit the
up-regulation of RTP/Drg1 expression induced by cobalt chloride,
Tiron and DFO (lanes 4-6).
[0028] FIG. 5B is a Western Blot showing the effect of carbon
monoxide (CO) on the hypoxic up-regulation of RTP/Drg1 expression.
In contrast to cultures incubated under standard conditions (20%
oxygen), culture of MDA-MB-231 cells under 1% oxygen for 24 h
resulted in increased RTP/Drg1 protein levels. This up-regulation
was inhibited in parallel cultures by inclusion of 30% CO in the
hypoxic atmosphere, which resulted in a 57% reduction in protein
levels (third lane), as determined by densitometry. In contrast, CO
was unable to inhibit the up-regulation of RTP/Drg1 expression
induced by cobalt chloride, Tiron and DFO (lanes 4-6).
[0029] FIG. 6 is a northern blot showing that RTP/Drg1 message is
expressed at higher levels in tissues isolated from preeclamptic
pregnancies than in tissues isolated from normal pregnancies.
CV=chorionic villi, BPD=basal plate decidua, MD=membrane decidua,
A=amnion (amniotic membrane).
[0030] FIG. 7 is a histogram showing augmented expression of uPAR
on cells cultured under hypoxic conditions. Analysis of uPAR
expression by HTR-8/SVneo cells using flow cytometry revealed an
average increase of 68% in the mean fluorescence intensity when
cells were cultured under hypoxic conditions and labeled with mAb
3937. This figure is representative of 7 independent
experiments.
[0031] FIG. 8 is a Northern bolt showing increased expression of
uPAR mRNA in cells cultured under hypoxic conditions. uPAR mRNA
levels increased 2.5-fold after only 4 h of hypoxic culture
compared with uPAR mRNA levels in cells cultured under standard
conditions. The levels of uPAR transcript increased 5-fold at 6 h
of culture under hypoxia and remained high at 8 and 24 h. Relative
levels of uPAR mRNA were determined with a SigmaGel gel analysis
program using 28S rRNA to correct for differences in the amount of
RNA loaded onto the gel.
[0032] FIG. 9 is a Northern blot showing that vascular endothelial
cell growth factor (VEGF) does not induce uPAR mRNA in HTR-8/SVneo
cells cultured under normoxic conditions.
[0033] FIG. 10 is a graph showing dose dependant binding of
.sup.125I-prourokinase to human umbilical vein endothelial cells
(HUVEC) under standard (solid squares) and hypoxic (open triangles)
conditions. This figure is representative of three independent
experiments, in which a mean increase of 46% in the binding of
[.sup.125I]-prourokinase to cells cultured under hypoxic conditions
was observed. Error bars indicate standard error of triplicate
samples for each point.
[0034] FIG. 11 is a Northern blot showing the effect of hypoxia,
carbon monoxide, cobalt chloride and Tiron on the levels of uPAR
mRNA in HTR-8/SVneo cells. Cells were cultured for 24 h under the
conditions listed under each lane of the figure. Levels of uPAR
mRNA were increased 2.8, 1.8, 3.5 and >10-fold, respectively,
within cells cultured under hypoxic (1% O.sub.2) conditions,
hypoxic conditions in the presence of 20% carbon monoxide, and
standard (20% O.sub.2) conditions in the presence of either cobalt
chloride or Tiron, in comparison to cells cultured under standard
conditions alone (lane 1). Carbon monoxide reduced the
hypoxia-mediated increase in uPAR mRNA by 35%.
[0035] FIG. 12 is a graph showing inhibition of hypoxia-induced
uPAR expression by carbon monoxide. HTR-8/SVneo cells were
incubated for 24 h under standard (20% O.sub.2) or hypoxic (1%
O.sub.2) conditions, or hypoxic conditions in the presence of 20%
carbon monoxide. The expression of uPAR was then assessed by flow
cytometry using mAb 3937. Carbon monoxide inhibited the
hypoxia-induced expression of uPAR by 56%. Data represent the
mean.+-.standard error of 4 independent experiments.
[0036] FIG. 13 is a photograph showing zymographic analysis of
plasminogen activators present in the medium of HTR-8/SVneo cell
cultures incubated for 8, 12 and 24 h under normoxic or hypoxic
conditions. Casein and plasminogen were incorporated into the
acrylamide prior to polymerization as described (Graham CH, et al.,
Exp Cell Res 206:204 (1993). Samples of serum-free medium
containing 200 ng of protein were loaded onto each lane and
separated by electrophoresis. Following an overnight incubation in
5 mM CaCl.sub.2 in TRIS buffer, gels were stained with Coomassie
R-250 in 10% acetic acid/40% methanol and destained in 10% acetic
acid/40% methanol. Clear areas represent caseinolytic activity.
Note caseinolytic bands at 50-55 kDa corresponding in size to uPA,
and that at 24 h of hypoxic culture the caseinolytic bands were not
discernible.
[0037] FIG. 14 is a graph illustrating that hypoxia induces the
expression of uPAR on MDA-MB-231 cells. Analysis of uPAR expression
by cells using flow cytometry revealed an average increase of 54%
in the mean fluorescence intensity when cells were cultured under
1% O.sub.2 and labeled with mAb 3937 against the human uPAR.
Culture under 4% O.sub.2 resulted in a more moderate (24%) increase
in cell surface uPAR. The latter increase, however, was
significantly lower than the increase observed in cells cultured
under 1% O.sub.2. Bars represent the mean relative fluorescence
intensity of 5 independent experiments+S.E. Data were analyzed by a
one-way repeated measures ANOVA followed by a post-hoc Newman-Keuls
multiple comparisons test for a significant statistic
(p<0.05).
[0038] FIG. 15 is a histogram showing that cobalt chloride induces
uPAR expression on MDA-MB-231 cells. Analysis of cells cultured
under standard conditions in the presence of 100 .mu.M cobalt
chloride revealed a 1.9-fold mean increase in uPAR levels as
compared with uPAR levels in cells cultured under standard
conditions alone. The data presented were taken from 1 of 2
experiments in which there was a 2.6-fold and 1.2-fold increase,
respectively, in relative fluorescence intensity in cells incubated
with cobalt chloride.
[0039] FIG. 16 is a Northern blot and a graph showing the time
course for hypoxia-induced increase in uPAR mRNA. Urokinase
receptor mRNA levels in MCF-10AT3B breast tumor cells cultured
under standard conditions (0 h) or hypoxia (1% O.sub.2) for 2, 16
and 24 h as determined by Northern blot analysis. Transcript levels
remained high between 2 and 16 h of hypoxic culture and returned to
near-control values by 24 h. 18S ribosomal RNA labeled with
ethidium bromide was used to correct for differences in the loading
of the agarose gel.
[0040] FIG. 17 is a Northern blot and a graph showing the effect of
culture for 0, 2, 4, 6, 12 and 24 h under hypoxic conditions, as
well as for 24 h under hypoxic conditions in combination with 30%
CO, on uPAR mRNA levels in MDA-MB-231 breast carcinoma cells. In
these cells, maximum levels of uPAR transcript were observed at 24
h of hypoxic culture. Compared with cells cultured for 24 h under
hypoxic conditions alone, culture of cells for a similar length of
time with 30% CO in the hypoxic atmosphere resulted in a 33%
decrease in the levels of uPAR mRNA.
[0041] FIG. 18 is a Northern blot and a graph showing the effect of
hypoxia, cobalt chloride (CoCl.sub.2) and Tiron on uPAR mRNA levels
in MDA-MB-231 cells. Densitometric analysis revealed a 4.5-fold
increase in uPAR mRNA levels in cells cultured under hypoxia (1%
O.sub.2) as compared to uPAR levels in cells cultured under
standard conditions. Similarly, culture under standard conditions
in the presence of 100 .mu.M cobalt chloride or 30 mM Tiron
resulted in 6- and 8-fold increases in uPAR mRNA levels
respectively. The results shown here represent 4 experiments
exhibiting similar effects.
[0042] FIGS. 19A-19D show zymographic analysis of the plasminogen
activator profiles in the conditioned serum-free medium of
MDA-MB-231 cells. Clear areas within the gels represent
caseinolytic activity resulting from activation of plasminogen.
Note the presence of caseinolytic bands at 50-55 kDa which likely
represent uPA (FIG. 19A and FIG. 19C), as incubation of the gels in
the presence of 100 mM amiloride, an inhibitor of uPA, prevented
the clearing of casein (FIG. 19B and FIG. 19D). In the absence of
plasminogen, caseinolytic bands were not observed (not shown).
Compared with standard cultures, plasminogen activator levels were
reduced in the medium from cultures exposed to hypoxia at all time
points (FIG. 19A). In contrast, cell-associated uPA levels were
increased in the hypoxic cultures or in cultures treated with
cobalt chloride (FIG. 19C). Furthermore, presence of CO in the
hypoxic atmosphere prevented the effect of hypoxia on
cell-associated uPA increases.
[0043] FIG. 20 is a graph illustrating in vitro invasion through
Matrigel by MDA-MB-231 breast carcinoma cells. An 8-fold increase
in the number of cells reaching the underside of the polycarbonate
membrane was observed when the assay was performed under 1% O.sub.2
as compared to 20% O.sub.2. Presence of 10 .mu.g/ml anti-uPAR mAb
3936 under hypoxic conditions abrogated the effect of low oxygen on
invasion. Bars represent the mean number of cells that invaded in 6
independent assays.+-.standard error
[0044] FIG. 21 is a graph showing APO-induced erections at
different frequencies of APO administration. Curve 1 shows erectile
response at administration frequencies of 0.5, 3, 5, 7, 12, 24, 48
hours after initial time point. Curve 2 shows erectile response at
administration intervals of 0.5, 4, 12, 24, 48 hours after initial
time point (n=6).
[0045] FIG. 22 is a graph showing APO-induced erectile response
after a single administration of 25, 35 and 50 mg/kg flutamide at
intervals of 0.5, 4, 12, 24, 48 hours after flutamide
administration (n=8).
[0046] FIG. 23 is a graph showing APO-induced erections after
administration of 50 mg/kg flutamide (n=4) and 500 mg/kg p,p-DDE
(n=4) at intervals of 0.5, 4, 12, 24, 48 hours and 2 weeks after
compound administration. At two weeks, p,p-DDE erectile response
was significantly different from both control and 50 mg/kg
flutamide responses.
[0047] FIG. 24 is a graph showing APO-induced erectile response of
p,p-DDE treated rats after testosterone supplementation of 480
ug/kg, 1.2 and 2.4 mg/kg tested at intervals of 0.5, 4 and 12 hours
after administration (n=4).
[0048] FIG. 25A is a bright field photomicrograph of normal
chorionic villi obtained at full gestation.
[0049] FIG. 25B is a dark field photomicrograph of the normal
chorionic villi shown in FIG. 25A. The tissue section was incubated
with antisenee radiolabeled RTP/Drg1 cRNA probe. The white dots are
hybridization grains which are indicative of RTP/Drg1 (PROXY-1)
mRNA expression.
[0050] FIG. 25C is a bright field photomicrograph of preeclamptic
chorionic villi obtained at full gestation.
[0051] FIG. 25D is a dark field photomicrograph of the preeclamptic
chorionic villi shown in FIG. 25C. The tissue section was incubated
with antisenee radiolabeled RTP/Drg1 cRNA probe. The white dots are
hybridization grains which are indicative of RTP/Drg1 (PROXY-1)
mRNA expression. Note the higher number of hybridization grains in
tissue isolated from preeclamptic pregnancies compared with normal
tissue (compare FIGS. 25D and 25B).
DETAILED DESCRIPTION OF THE INVENTION
[0052] The vascular system is generally controlled by three classes
of physiological systems: neural, humoral (hormonal), and local
(e.g., at the level of endothelial cells that line the vasculature
and vascular smooth muscle). The response of any one of these
systems to a hypoxic state varies. Moreover, different
circumstances will elicit different responses in each system. For
example, endothelial cells can respond to hypoxic conditions by
increasing endothelin secretion, by up-regulation of a metabolic
product such as von Villebrand factor, or by increasing metabolic
processes such as arginine metabolism, thereby increasing the
byproducts ADMA and L-NMMA. Further, other circumstances may modify
the phenotype of vascular smooth muscle cells or other cells, such
that the cells alter their expression pattern of a series of
factors such as urokinase-type plasminogen activator receptor
(uPAR), plasminogen activator inhibitor-1 (PAI-1) and RTP/Drg1.
Indeed, the up-regulated expression of various genes and their
products in response to hypoxic conditions occurs in a wide range
of cells, and neoplastic cells in general.
[0053] According to a broad aspect, this invention relates to
methods for diagnosing hypoxia, endothelial dysfunction or a
vascular condition or circulatory condition, such as a condition
associated with a reduction in blood flow and/or oxygen delivery
within an anatomical site or system. As used herein, the term
"hypoxia" refers to a condition in which the oxygen level is
reduced below the normal physiological range in a particular
organism, system, organ, tissue, cell, organelle, macromolecule
(e.g., protein) or molecule. The term "vascular condition" refers
to the state, which can be abnormal or normal, of vascular tissue,
blood flow and/or blood components. A vascular condition can result
in hypoxia However, it is appreciated that hypoxia can occur in the
absence of a vascular condition (e.g., altitude sickness). Further,
hypoxia can induce a vascular condition. The term "diagnosing", as
used herein, encompasses monitoring, assessing, evaluating and
detecting. Thus, as described herein, the invention can be used,
for example, to evaluate and/or monitor a therapeutic regimen or to
assess an individual's risk for a vascular condition. Typically a
vascular condition to which the diagnostic methods of the invention
apply is one in which the vasculature of the affected tissue or
system is altered, such that blood flow to the tissue or system is
reduced and the tissue or system is rendered hypoxic. Vascular,
circulatory or hypoxic conditions to which the diagnostic methods
of the invention apply are those associated with, but not limited
to, maternal hypoxia (e.g., placental hypoxia, preeclampsia),
abnormal pregnancy, peripheral vascular disease (e.g.,
arteriosclerosis (atherosclerosis, transplant accelerated
arteriosclerosis), deep vein thrombosis), erectile dysfunction,
cancers, renal failure, stroke, heart disease, sleep apnea, hypoxia
during sleep, female sexual dysfunction, fetal hypoxia, smoking,
anemia, hypovolemia, vascular or circulatory conditions which
increase risk of metastasis or tumor progression, hemorrhage,
hypertension, diabetes, vasculopathologies, surgery (e.g.,
per-surgical hypoxia, post-operative hypoxia), Reynaud's disease,
endothelial dysfunction, regional perfusion deficits (e.g., limb,
gut, renal ischemia), myocardial infarction, stroke, thrombosis,
frost bite, decubitus ulcers, asphyxiation, poisoning (e.g., carbon
monoxide, heavy metal), altitude sickness, pulmonary hypertension,
sudden infant death syndrome (SIDS), asthma, chronic obstructive
pulmonary disease (COPD), congenital circulatory abnormalities
(e.g., Tetralogy of Fallot) and Erythroblastosis (blue baby
syndrome). In particular embodiments, the invention is a method of
detecting hypoxia or endothelial dysfunction in an individual.
[0054] The method of the invention can also be used to monitor
individuals receiving therapy, including prophylactic therapy, or
diagnostic evaluation for a vascular condition, a hypoxic condition
or a condition associated with endothelial dysfunction. For
example, an individual can be monitored while recovering from
surgery, while receiving antihypertensive therapy or while
receiving a therapy which modifies the circulation (e.g. vascular
surgery, angioplasty). An individual can also be monitored to
assess the impact of various levels of exercise, such as when
assessing exercise tolerance in cardiac patients (e.g., stress
test). The method of the invention can also be used forensically.
For example, the invention can be used to determine the time and/or
cause of death as well as the extent and/or duration of hypoxia
post-mortem.
[0055] In a particular embodiment, the invention relates to a
method of diagnosing preeclampsia, a condition in which trophoblast
cells, which under normal conditions invade the uterine wall and
stimulate an increase in vasculatity necessary to support the
placenta during pregnancy, are unable to stimulate an increase in
vasculatity. Apparently, the invasiveness of the trophoblasts is
decreased or altered. As a result, preeclampsia is characterized by
an ischemic condition.
[0056] The invention also contemplates the diagnosis of altered
vasculature such as reduced vascularity resulting in hypoxia within
tumors. Tumor hypoxia is correlated with a poor prognosis in cancer
patients, and it reduces the efficacy of treatments such as
chemotherapy and radiation therapy. The invention further
contemplates diagnostic applications in which a subject has chronic
hypoxia or has been exposed to a transient episode of hypoxia. Such
transient hypoxia may occur, for example, during surgery, as a
result of administration of agents such as anaesthetics and/or a
surgical procedure which transiently reduces blood flow. Hypoxia
can also be a consequence of trauma. Such transient hypoxia is also
one example of a condition under which potential for metastasis of
cancer cells, or the degree to which cells are invasive, may be
increased. Thus, the invention also relates to a method of
assessing an individual's risk for metastasis.
[0057] Cellular response to a hypoxic condition resulting from
altered vasculature may be characterized by any of the following,
either alone or in combination: a change in the number of copies of
one or more genes; a change in the level of expression of one or
more genes; a change in metabolic processes and the levels of their
substrates, products or by-products (i.e., metabolic indicators of
a hypoxic condition). Diagnostic methods of the invention comprise
subjecting one or more biological samples obtained from an
individual to one or more analyses for detecting and quantifying
the levels of a substance, (e.g., genes, gene products, metabolites
(e.g., a substrate of a metabolic reaction), or metabolic
by-products), whether the levels increase or decrease from
currently accepted normal levels. In one embodiment, the substance
is a cell-associated protein. A measure or measures obtained
through such analyses is compared to a standard such that a
vascular or hypoxic condition may be diagnosed on the basis of that
comparison. In a further embodiment, the invention is a method of
assessing an individual's risk for a vascular condition associated
with a reduction in the flow of blood. The method comprises
quantifying the levels of a substance (e.g., genes, gene products,
metabolites (e.g., a substrate of a metabolic reaction), or
metabolic by-products) in one or more biological samples isolated
from said subject, and determining whether the levels increase or
decrease from currently accepted normal levels, wherein risk
correlates with the degree to which said substance, such as a
RTP/Drg1 gene product, is increased or decreased from normal.
[0058] According to the invention a biological sample obtained from
an individual for the purpose of analysis may be any tissue sample,
cell or bodily fluid in which the substance (e.g., genes, gene
products, metabolites, metabolic by-products) of interest may be
present. Typical biological samples include a tissue sample such as
a biopsy obtained from the organ or system under consideration,
hair, blood, serum, plasma, leukocytes (e.g., T cells, B cells, NK
cells, macrophages, eosinophils, basophils, monocytes), saliva,
urine, breath, feces, semen, and the like. As used herein, the term
"individual" refers to any living organism and includes unicellular
and multicellular organisms, such as bacteria, yeasts, plants,
fish, birds and mammals, such as a human.
[0059] According to the invention, genes which undergo a change in
expression, such as an up-regulation of expression, in response to
a hypoxic condition include, for example, genes which could mark,
and in some cases have been shown to mark, the progression of
hypoxic injury, progression of abnormal vascular structural
changes, as well as vascular smooth muscle functions. For example
these genes include, but are not limited to, the urokinase-type
plasminogen activator receptor gene (uPAR), plasminogen activator
inhibitor-1 gene (PAI-1), and gene RTP/Drg1 (which is also referred
to as PROXY-1 (Protein Regulated by OXYgen)). In the analysis of a
gene or genes, the diagnostic method of the invention involves use
of suitable techniques for the identification of genes or gene
products, such as the polymerase chain reaction (PCR) in
combination with a probe or probes specific to the gene or genes,
or a fragment thereof, to produce copies of the gene or genes in
question, followed by, for example, Southern blot analysis
(Southern, J. Mol. Biol., 98:508 (1975)). Upon suitable analysis of
the data obtained, as described below, different abundance of such
a particular gene(s) or gene product(s) (e.g., mRNA, protein) in a
sample (e.g., tissue sample, fluid sample), relative to the
abundance of that gene(s) or gene product(s) according to a
standard or from another sample known to not have a vascular or
hypoxic condition, would be an indicator of hypoxia in the
individual from which the test sample was taken.
[0060] The substance or substances selected can be quantified
directly or indirectly using any suitable method, such as a method
based upon activity (e.g., catalytic activity) or a method which
measures the number of molecules of a particular substance (e.g., a
specific protein, a specific mRNA molecule). When the number of
molecules of a particular substance in a sample is measured, the
measured value can be expressed as an absolute quantity (e.g.
moles/g of sample) or relative to a reference sample.
[0061] Total cellular RNA can be isolated from a biological sample
using any suitable technique, such as, for example, the single-step
guanidinium-thiocyanate-phenol-chloroform method described by
Chomczynski et al. (Anal. Biochem., 162:156-159 (1987)). The level
of an mRNA of interest is then assayed using any appropriate
method, including northern blot analysis, S1 nuclease mapping,
polymerase chain reaction (PCR), reverse transcription in
combination with the polymierase chain reaction (RT-PCR), reverse
transcription in combination with ligase chain reaction (RT-LCR)
and PCR or LCR in combination with hybridization. Northern blot
analysis can be performed as described in Harada et al., Cell,
63:303-312 (1990), and S1 mapping can be performed as described in
Fujita et al., Cell 49:357-367 (1987). Levels of mRNA encoding a
protein of interest can be assayed using the RT-PCR method
described in Makino et al., Technique, 2:295-301 (1990), using a
set of oligonucleotide primers that will amplify
reverse-transcribed target mRNA. Methods for designing an
appropriate set of primers are well-known in the art.
[0062] According to the invention a metabolic indicator is any
compound, such as, for example, a protein, or any metabolite or
metabolic by-product, the production of which is changed in
response to a hypoxic condition. For example, a metabolic indicator
can be a protein which is expressed by a gene which is up-regulated
or down-regulated in response to hypoxia. A metabolic indicator can
be, for example, a urokinase-type plasminogen activator receptor
(uPAR), a plasminogen activator inhibitor-1 (PAI-1), the 43 kDa
protein encoded by RTP/Drg1 (see Examples 1-3). A metabolic
indicator can be a molecule (e.g., metabolite, catabolite,
anabolite) the production of which is changed as a result of a
vascular condition, hypoxia and/or endothelial dysfunction. For
example, a metabolic indicator can be, ADMA (asymmetrical dimethyl
arginine) or L-NMMA (nitric-mono-methyl arginine), which are
products of abnormal arginine metabolism which can occur during
hypoxia or an agent which can antagonize heme oxygenase, such as
zinc-protoporphyrin. Of course, a metabolic indicator can also be
any metabolite or derivative of these compounds, or any combination
thereof. A metabolic indicator can also be any compound which, when
present in the biological sample, has an effect on vascular
function and hence blood flow. Such metabolic indicators therefore
also include, for example, externally derived toxins and
contaminants. An analysis for a metabolic indicator can be any
suitable assay such as RIA or other methods well known in the art,
such as, for example, ELISA or the dipstick test. Subject to
appropriate data analysis, as discussed below, a difference in the
level of the indicator or indicators in the sample under analysis
indicates the presence of a vascular and/or hypoxic condition.
[0063] In addition, any indirect method for assessing whether a
tissue sample has been subjected to hypoxia can also be employed,
such as assessing cells for altered cell adhesion (see Example 2)
and cellular invasion assays (Examples 4 and 5). For Example, in
one embodiment, the invention is a method for detecting hypoxia in
an individual, comprising isolating cells from said individual and
evaluating the invasiveness of said cell in an in vitro assay as
described herein. In this embodiment, an increase in invasiveness
indicates that the individual has experienced hypoxia. In another
embodiment, an in vitro cellular invasion assay can be used to
assess an individuals risk for metastasis. In this embodiment,
increased invasiveness indicates an increased risk for metastasis.
It is preferred that the biological sample analyzed for assessing
the risk for metastasis does not contain cancerous cells.
[0064] Protein levels in biological samples can be assayed using
any suitable method known in the art. For example, when a protein
is an enzyme, the protein can be quantified based upon its
catalytic activity or based upon the number of molecules of the
protein contained in a sample. Antibody-based techniques may be
employed, such as, for example, immunohistological and
immunohistochemical methods for measuring the level of a protein of
interest in a tissue sample. For example, specific recognition is
provided by a primary antibody (polyclonal or monoclonal) and a
secondary detection system is used to detect presence (or binding)
of the primary antibody. Detectable labels can be conjugated to the
secondary antibody, such as a fluorescent label, a radiolabel, or
an enzyme (e.g., alkaline phosphatase, horseradish peroxidase)
which produces a quantifiable, e.g. colored, product. In another
suitable method, the primary antibody itself can be detectably
labeled. As a result, immunohistological labeling of a tissue
section is provided. In one embodiment, an extract is produced from
a biological sample (e.g., tissue, cells) for analysis. Such an
extract (e.g., a detergent extract) can be subjected to
western-blot or dot/slot assay of the level of the protein of
interest, using routine immunoblotting methods (Jalkanen et al., .J
Cell. Biol., 101:976-985 (1985); Jalkanen et al., J. Cell. Biol.,
105:3087-3096 (1987)).
[0065] Other useful antibody-based methods include immunoassays,
such as the enzyme-linked immunosorbent assay (ELISA) and the
radioimmunoassay (RIA). For example, a protein-specific monoclonal
antibody, can be used both as an immunoadsorbent and as an
enzyme-labelled probe to detect and quantify protein of interest.
The amount of such protein present in a sample can be calculated by
reference to the amount present in a standard preparation using a
linear regression computer algorithm (see Iacobilli et al., Breast
Cancer Research and Treatment, 11:19-30 (1988)). In another
embodiment, two different monoclonal antibodies to the protein of
interest can be employed, one as the immunoadsorbent and the other
as an enzyme-labelled probe.
[0066] It is appreciated that some substances which are suitable
indicators of hypoxia and/or a vascular condition are not found in
all biological samples. Thus, the substance or substances to be
measured will be selected based upon the nature of the biological
sample. For example, when the biological sample is a tissue biopsy
the substance to be measured can be a gene product which is
expressed in the tissue at different levels under normoxic and
hypoxic condition. In a preferred embodiment, a substance which can
be detected in a wide variety of biological samples is selected for
analysis. When such a substance is selected, a plurality of
distinct biological samples can be analyzed in a single assay. A
preferred substance which can be detected in a wide variety of
biological samples is a product (e.g., mRNA, protein) of the
RTP/Drg1 gene. Substances which are expressed in particular tissues
or cells and substances which can be detected in a variety of
samples can be identified using suitable methods, such as the
methods described herein.
[0067] For example, genes which are differentially expressed under
normoxic and hypoxic conditions can be identified by differential
display RT-PCR. The genes can then be isolated and expression
patterns can be determined using conventional techniques. If
desired, an antibody (e.g., anti-sera, monoclonal antibody) can be
raise, against a purified, recombinant or synthetic protein or
fragment thereof and used to assess the tissue distribution of the
protein (see Example 3).
[0068] The contents of Maniatis, T., et al., Molecular Cloning:
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y. (1982), and Sambrook, J. et al., Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y. (1989), as well as all references cited herein are
hereby incorporated by reference.
[0069] According to the invention, a standard against which the
above measure or measures from test samples are compared may be
data obtained from a data bank corresponding to currently accepted
normal levels of the genes, gene products, metabolites, and
metabolic by-products under analysis. In situations such as those
where standard data is not available, the methods of the invention
can further comprise conducting corresponding analyses in a second
set of one or more biological samples known not to have been
exposed to hypoxia. Such additional biological samples can be
obtained, for example, from the individual under consideration
prior to the onset of a vascular or hypoxic condition, or from
unaffected members of the public or in the case of an investigation
of a localized site within an individual, from an unaffected site
within said individual.
[0070] According to the methods of the invention, the comparison of
the above measure or measures can be a straight-forward comparison,
such as a ratio, or it can involve weighting of one or more of the
measures, relative to, for example, their importance to the
particular situation under consideration. The comparison can also
involve subjecting the measurement data to any appropriate
statistical analysis. It is important to note that in the
diagnostic procedures of the invention, one or more biological
samples obtained from an individual can be subjected to a battery
of analyses in which a desired number of genes, gene products,
metabolites, and metabolic by-products are sought to be quantified.
In any such diagnostic procedure it is possible that one or more of
the measures obtained will render an inconclusive result;
accordingly, data obtained from a battery of measures can provide
for a more conclusive diagnosis. It is for this reason that an
interpretation of the data based on an appropriate weighting scheme
and/or statistical analysis is desirable.
[0071] It should be noted that the diagnostic methods of the
invention are not limited to the detection of endogenously-derived
substances. Exogenous agents present in the body may function to
disrupt physiological processes and produce conditions which
resemble or result in hypoxia. For example, cobalt and nickel,
obtained from compounds such as cobalt chloride and nickel
chloride, can mimic hypoxic conditions which result from deficient
blood flow by virtue of the fact that they can disrupt
oxygen-sensing heme proteins. Thus, although a pathological
condition caused by cobalt- or nickel-mediated disruption of an
oxygen-sensing heme protein may not be directly caused by an
abnormal or altered vascular condition, the deleterious symptoms
resulting from such binding are analogous to those produced by
hypoxia resulting from deficient blood flow. In addition to cobalt
and nickel, other exogenous agents may similarly bind to heme, such
as, for example, iron, ruthenium, rhodium, palladium, osmium,
iridium, and platinum. These agents may be environmental
contaminants obtained by ingestion and which bioaccumulate within
the body, such as in fat deposits. Known heme proteins include
globins and cytochromes. The diagnostic methods of the invention
are therefore useful for detecting the presence of such exogenous
agents.
[0072] Other exogenous agents may bioaccumulate within the body and
disrupt physiological processes that directly affect vascular
condition. For example, there are those substances which act to
modify systems such as, for example, endocrine systems. An example
of such an endocrine disruptor substance is a DDT metabolite such
as p,p-DDE. DDT is an environmental contaminant which is
particularly common in third world countries. There are, of course,
a host of other compounds which act as anti-androgenics or as
anti-estrogenics. In the case of p,p-DDE, a measure of the level of
testosterone in an individual who has a body burden of p,p-DDE may
reveal that the individual has normal levels of testosterone;
however, because of the body burden of p,p-DDE, there is a subtle
blockade of the actions of testosterone. The individual would
therefore appear normal with respect to testosterone levels, but
would in fact be sub-androgenic in terms of the required amount of
testosterone for normal function. Male erectile dysfunction is an
example of a vascular disorder that is known to be related to a
sub-androgenic condition. Thus, using the diagnostic methods of the
invention, one can determine, for example, a ratio of testosterone
levels to anti-androgen levels within the body to determine whether
an individual has the potential for an environmentally-induced
vascular disorders such as erectile dysfunction.
Exemplification
[0073] Materials and Methods
[0074] Cells. Human MDA-MB-231 breast cancer cells were cultured in
RPMI 1640 medium (Gibco BRL, Grand Island, N.Y.) supplemented with
5% fetal bovine serum (FBS; Gibco BRL). These cells were initially
isolated from a single pleural effusion obtained from a 51-year old
woman in 1973 (Cailleau, R., et al., J.Natl. Cancer Inst.
53:661-674 (1974)). HTR-8/SVneo cells were obtained from explant
cultures of human first trimester placenta and immortalized by
transfection with a cDNA construct containing the SVneo large T
antigen as described (Graham, C. H., et al., Exp. Cell Res.
206:204-211 (1993)). These cells have been previously characterized
and have been maintained in culture for over 120 passages in RPMI
1640 medium supplemented with 5% FBS. They exhibit a high
proliferation index and share various phenotypic similarities with
the non-transfected parent HTR-8 cells such as in vitro invasive
ability and lack of tumorigenicity in nude mice (Graham, C. H., et
al., Exp. Cell Res. 206:204-211 (1993)). Tumorigenic, but
non-metastatic, human breast cancer MCF10A1T3B cells were provided
by Dr. Bruce Elliot, Queen's University, Kingston, ON. These cells
were obtained following injection of the H-ras-transformed
non-tumorigenic MCF10A1 breast epithelial cells into nude mice and
were maintained in DMEM/F12 supplemented with 5% FBS, 10 .mu.g/mL
insulin, 0.2 ng/mL epidermal growth factor, and 0.5 .mu.g/mL
hydrocortisone. Human aortic smooth muscle cells (HASMC) were a
kind gift of Dr. Keith McCrae, Case Western Reserve University,
Cleveland, Ohio. They were cultured in M199 medium (Gibco BRL)
supplemented with 10% FBS.
[0075] Culture Conditions. For culture under hypoxic conditions,
cells were placed in airtight chambers (BellCo Biotechnology,
Vineland, N.J.) which were flushed with a 5% carbon dioxide/95%
nitrogen mixture until the oxygen concentration, measured with a
Miniox 1 oxygen analyzer (Catalyst Research Corp., Owings Mills,
Md.), was 0%. The cells were incubated within the sealed chambers
for up to 60 h at 37.degree. C. Under these conditions, the oxygen
concentration equilibrates within 1-2 h and remained at
approximately 1% throughout the entire incubation period. At these
levels, the PO.sub.2 values reach 10-15 mmHg at the bottom of the
tissue culture plate as determined with a transcutaneous pO.sub.2
analyzer (Kontron Scientific Ltd., Mississauga, ON). For culture
under 2-10% oxygen, cells were incubated for 24 h at 37.degree. C.
in a multigas (nitrogen-carbon dioxide) incubator (Forma
Scientific, Marietta, Ohio.) previously allowed to equilibrate at
2-10% oxygen, 5% carbon dioxide, balance nitrogen. Control cultures
were incubated at 20% oxygen/5% carbon dioxide, for 24 h, in a
Sanyo carbon dioxide incubator (Esbe Scientific, Markham, ON).
[0076] To determine whether hypoxia regulates the expression of
certain genes (e.g., PAI-1, uPAR, RTP/Drg1 ) via an iron-containing
heme protein, cells were cultured for up to 72 h at 20% oxygen in
the presence or absence of either 100 .mu.M cobalt chloride, or 30
mM sodium 4,5-dihydroxybenzene-1,3-disulfonate (Tiron), or 100
.mu.M desferrioxamine mesylate (DFO) (Sigma Chemical CO., St.
Louis, Mo.). Further confirmation of the role of a heme protein in
hypoxic responses can be achieved by culturing cells under hypoxia
in the presence of carbon monoxide, which maintains the heme
protein in the oxy state and thereby blocks heme protein-mediated
hypoxic responses. Thus, cells were also cultured for 24 h at
37.degree. C. under hypoxic conditions in the presence of 30%
carbon monoxide.
[0077] Determination of Cell Viability. As an indirect measure of
cell viability, lactate dehydrogenase (LDH) levels were assessed in
the culture medium of HTR-8/SVneo and MDA-MB-231 cells incubated in
triplicate plates under 20% oxygen or 19% oxygen for up to 72 h,
using a kit from Sigma Diagnostics (St. Louis, Mo.). This assay is
based on a colorimetric reaction which involves the reduction or
pyruvate to lactate at a rate proportional to the amount of LDH
present.
[0078] RNA Extraction and mRNA Differential Display. Total RNA was
extracted from HTR-8/SVneo and MDA-MB-231 cells cultured under
either standard (20% oxygen) or hypoxic (1% oxygen) conditions by
the acid guanidium phenol-chloroform method (Chomczynski, P. and
Sacchi, N. Analyt.Biochem. 162:156-159 (1987)). The RNA was then
treated with ribonuclease-free deoxyribonuclease I (Promega Corp.,
Madison, Wis.) to remove contaminating genomic DNA and quantified
spectrophotometrically. Differential display was performed
according to the method of Liang and Pardee (Liang, P. and Pardee,
A. B. Science 257:967-971 (1992)) using an RNAImage kit (GenHunter,
Brookline, Mass.) as described (Pak, B. J., et al., Placenta
19:483-488 (1998)). Briefly, reverse transcription was performed on
0.2 .mu.g of total RNA at 37.degree. C. using MMLV reverse
transcriptase and one of three different single-base anchored
oligo-dT primers (H-T.sub.11A, H-T.sub.11C, and H-T.sub.11G). The
resulting cDNA was then subjected to PCR amplification, in the
presence of [.sup.33p]dATp (DuPont NEN, Markham, ON), using the
same anchored primers in combination with one of eight degenerate
oligonucleotide primers (HAP-1-8). PCR parameters were as follows:
94.degree. C., 30 sec; 40.degree. C., 2 min; 72.degree. C., 30 sec
for 40 cycles, then 72.degree. C. for 7 min. cDNA products obtained
were separated by electropheresis through 6% polyacrylamide-8M urea
sequencing gels. The gels were vacuum-dried onto blotting paper,
and autoradiographed for 1-3 days on DuPont Reflection NEF X-ray
film (DuPont Canada, Inc., Mississauga, ON). Bands displaying
differential intensities were excised, re-amplified using the above
PCR conditions, and cloned into pCR2.1 or pCRII vectors
(Invitrogen, San Diego, Calif.). The nucleotide sequence of the
subcloned PCR fragments was determined by the dideoxynucleotide
sequencing method at the Core Facility for Protein/DNA Chemistry
(Queen's University, Kingston, ON). Comparison of DNA homology with
the GenBank database was performed using the BLAST 2.0 algorithm
(blastn with default parameters, Altschul, S. F., et al., Nucleic
Acids Res 25(17):3389-3402 (1997)).
[0079] Northern Blot Analysis. Total RNA was isolated from cell
lines as described above. Aliquots of 20 .mu.g were denatured and
subjected to electrophoresis in 1% agarose-formaldehyde gels
(Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning:
A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y. (1989)). RNA was transferred to nylon membranes
(Micron Separations, Inc., Westboro, Mass.). After prehybridization
at 42.degree. C. for 2-3 h in 50% formamide, 5.times.Denhardt's
solution, 0.5% sodium dodecyl sulfate (SDS), 6.times.SSC
(1.times.SSC: 0.15M NaCl, 15 mM sodium citrate, pH 7.0), and 100
.mu.g/mL denatured salmon sperm DNA, membranes were hybridized for
a period of time of overnight (.about.18 h) to about 72 h at
42.degree. C. with a cDNA probe (e.g., RTP/Drg1, PAI-1 (PAI-1 cDNA
provided by Dr. Keith McCrae, Temple University School of Medicine,
Philadelphia, Pa.), uPAR (Higazi A, et al., J Biol Chem 266:12752,
(1995)) pre-labeled with [.sup.32P]-dCTP using a Pharmacia
Oligolabelling kit (Pharmacia Biotech, Piscataway, N.J.). The
hybridization solution contained 6.times.SSC, 0.5% SDS, 100
.mu.g/mL denatured salmon sperm DNA, 50% formamide and cDNA probe.
After hybridization, the membranes were washed with 2.times.SSC and
0.5% SDS at room temperature for 15 min, 2.times.SSC and 0.1% SDS
at room temperature for 15 min, and 0.1.times.SSC and 0.5% SDS for
30 min. Dupont Reflection NEF film Dupont Canada, Inc.,
Mississauga, ON) was exposed to the membranes for 1-3 days at
-80.degree. C. Bands on radiographic film were analyzed using a
SigmaGel gel analysis software package (Jandel Scientific Software,
San Rafael, Calif.).
[0080] Determination of PAI-1 Levels in the Culture Medium. The
levels of PAI-1 in the conditioned medium of HTR-8/SVneo cells
cultured under standard or hypoxic conditions for 8, 12 and 24
hours were measured and compared using a specific PAI-1 ELISA kit
(American Diagnostica, Greenwich, Conn.), which detects latent and
active forms of PAI-1 and PAI-1 complexes.
[0081] Cell Adhesion Assay. Wells in 96-well tissue culture plates
were coated with 100 .mu.l of 10 .mu.g/ml of vitronectin or 10
.mu.g/ml of BSA in PBS and left to bind to the plastic surface
overnight at 4.degree. C. Following 2-3 gentle washes with PBS, the
wells were blocked with 100 .mu.l of 1 mg/ml BSA in RPMI medium for
1-2 hours at 37.degree. C. During this time, the cells were
harvested with 5 mM EDTA in PBS at 4.degree. C., washed once or
twice in cold BSA/RPMI medium and adjusted to a concentration of
5.times.10.sup.5 cells/ml. One hundred microliters of the cell
suspension were then added to each well and the cells were allowed
to adhere for 45 minutes at 37.degree. C. under either standard
(20% O.sub.2) or hypoxic (1% O.sub.2) conditions. The wells were
washed gently with warm PBS 3 or 4 times to remove unbound cells,
each time inverting the plates and shaking them until the BSA
control wells were almost clear of cells. The remaining cells were
fixed with 4% paraformaldehyde in PBS for 1-2 hours and stained
with 1% toluidine blue in 1% sodium borate for 2 hours. Finally,
excess stain was removed with distilled water, the plates were
allowed to dry and their absorbance was read at 570 n using a
Dynatech MR4000 plate reader (Dynatech Laboratories Inc.,
Chantilly, Va.).
[0082] Three-Dimensional Multicellular Aggregates. Multicellular
aggregates were generated as described (Graham, C. H., et al.,
J.Natl. Cancer Inst. 86:975-982 (1994); Kobayashi, H., et al.,
Proc.Natl.Acad.Sci. USA 90:3294-3298 (1993)). Briefly, each well of
24-well plates was coated with 0.25 mL of melted 1% sea-plaque
agarose in serum-free medium. After the agarose solidified,
1.times.10.sup.5 cells in 1 mL of complete medium were plated in
each well and incubated at 37.degree. C., 5% carbon dioxide, for
3-5 days to allow for aggregate formation. Under these conditions,
the cells could not attach to the tissue culture plates and single
multicellular aggregates of approximately 0.5 mm in diameter were
evident at the end of the incubation period.
[0083] Production of Anti-Drg1 Antiserum. After transfection of E.
coli with an almost full-length (first two codons lacking) Drg1
cDNA cloned into the pProEXHT expression vector, fusion protein was
harvested from bacterial lysates by affinity chromatography with
Ni-NTA agarose (Qiagen), followed by denaturing batch purification
(Qiagen) according to the manufacturer's protocol. Immunization of
rabbits was performed by repeated intradermal injection of 100
.mu.g of the DRG1 fusion protein with (in)complete Freund's
adjuvant (Eurogentech). Specificity of the antiserum was assessed
by Western blotting and immunohistochemistry. In Western blots,
using protein isolated from HT29 and Caco2 colon cancer cells, as
well as proteins extracted from E. coli cells transfected with the
Drg1 construct or the empty vector, specificity was confirmed by
the occurrence of a 43-kDa (Caco2 and HT29 cells) or a 53.5-kDa
(recombinant) band, the latter lacking in empty vector-transfected
E. coli. Immunoreactivity on tissue sections was abolished by
pre-incubation of the antiserum with purified recombinant Drg1
protein.
[0084] Western Blot Analysis. To examine levels of RTP/Drg1
protein, cells were lysed with buffer containing 40 mM HEPES pH
7.2, 100 mM NaCl, 20% glycerol, 0.1 mM EDTA pH 8.0, 0.2% Triton
X-100 (polyoxyethylene (10) isooctylphenyl ether), 1 mM DTT, and 2
mM PMSF, and centrifuged briefly at 4.degree. C. The supernatants
were collected and stored at 80.degree. C. until use. SDS-PAGE was
performed and resolved proteins were transferred to Immobilon-P
membranes (Millipore Corp., Bedford, Mass.) using a semi-dry
transfer cell (Bio-Rad Laboratories, Mississauga, ON). Membranes
were blocked by incubation overnight at 4.degree. C. in a
PBS-buffered solution containing 0.01% Tween 20
(polyoxyethylene(20) sorbitan monolaurate) (PBS-T) and 5% casein.
The blots were then incubated with polyclonal rabbit anti-Drg1
antiserum followed by incubation with a peroxidase labeled goat
anti-rabbit IgG secondary antibody (Vector Lab. Inc., Burlingame,
Calif.). Antigen was detected by enhanced chemiluminescence (ECL,
Amersham Canada Inc., Oakville, ON) and exposure of the membrane
onto Dupont Reflection NEF film (Dupont Canada, Inc., Mississauga
ON).
[0085] Immunohistochemistry. RTP/Drg1 protein in sections of
HTR-8/SVneo and MDA-MB-231 multicellular aggregates was localized
by immunohistochemistry using the avidin-biotin peroxidase method
(Hsu, S. M., et al., J.Histochem.Cytochem. 29:577-580 (1981)).
Tissue blocks fixed in paraffin were cut into 4-.mu.m-thick
sections, deparaffinized, and immersed in 0.3% hydrogen peroxide in
methanol for 30 min to abolish endogenous peroxidase activity. The
sections were blocked with 10% normal goat serum (NGS) for 20 min
to reduce nonspecific staining. Anti-Drg1 antiserum diluted with 2%
NGS (1:500) was applied to the sections and incubated overnight at
4.degree. C. This was followed by incubation with a 1:200 dilution
of a biotinylated goat anti-rabbit IgG (Vector Laboratories,
Burlingame, Calif.) for 30 min at room temperature and a subsequent
30 min incubation with Vectastain ABC reagent (Vector
Laboratories). Antigenic sites were localized by incubation with
diaminobenzidine solution and hydrogen peroxide for 5 min. Sections
were counterstained with Gill's No. 2 hematoxylin, dehydrated, and
mounted. Negative controls consisted of sections incubated with
preimmune serum used at the same concentration as the anti-Drg1
antiserum.
[0086] Determination of uPAR expression by flow cytometry. For flow
cytometry, cells were released from flasks by incubation in cold
PBS containing 5 mM EDTA. One million cells were then incubated for
1 h, at 4.degree. C., with either 10 .mu.g/ml of mAb 3937, or
control mouse IgG.sub.2a, used at the same concentration. Bound
antibody was detected using FITC-conjugated goat anti-mouse
immunoglobulin. Cells were then fixed with 2% paraformaldehyde in
PBS prior to analysis using a Coulter Elite Flow Cytometer.
[0087] Determination of uPAR expression by urokinase binding
analysis. Measurement of uPAR expression by ligand binding analysis
was performed using [.sup.125I]-prourokinase as the ligand, as
described (Zini J M, et al., Blood 79:2917 (1992)). Prourokinase
was radiolabeled with .sup.125I, using Iodobeads, to a specific
radioactivity of at least 10.sup.6 cpm/.mu.g. Cells were then
chilled to 4.degree. C., washed with cold PBS containing 1% BSA,
and incubated for 2 h with increasing concentrations of
[.sup.125I]-prourokinase in the absence (to determine total
binding) or presence (to determine non-specific binding) of a
100-fold molar excess of unlabeled prourokinase. Specific binding
was defined as the difference between total and non-specific
binding, and analyzed by non-linear curve fitting methods (least
squares method) using the Kaliedograph software program (Synergy
Software, Reading, Pa.).
[0088] In vitro invasion assay. An assay which employs
reconstituted basement membrane (Matrigel; Collaborative Biomedical
Products, Bedford, Mass.) as the substrate for invasion was used to
determine the effect of hypoxia on the invasiveness of tumor cells.
Costar Transwell inserts (6.5 mm diameter polycarbonate membrane, 8
.mu.m pore; Corning Costar Corp., Cambridge, Mass.) were coated
with 100 .mu.l of a 1 mg/ml solution of Matrigel diluted in cold
serum-free culture medium, placed in the wells of a 24-well tissue
culture plate and allowed to air-dry for 12 h in a laminar flow
cabinet. After reconstituting the Matrigel by incubating for 1 h
with 100 .mu.l of serum-free medium, 5.0.times.10.sup.4 cells in
100 .mu.l aliquots of serum-containing medium were added to the
Transwells. Following a 24-h incubation under either 20% or 1%
O.sub.2 in the absence or presence of 10 .mu.g/ml blocking
anti-uPAR antibody (3936), or under 1% O.sub.2+30% CO (to assess
the role of a heme protein on invasion), cells on the surface of
the Matrigel-coated polycarbonate membrane (non-invading cells)
were removed by scraping with a cotton swab. Cells which invaded
through the Matrigel and the pores of the underlying membrane were
fixed for 10 min in Carnoy's fixative (25% acetic acid, 75%
methanol) and stained for 3 h in 1% toluidine blue, 1% sodium
borate. Following several washes in tap water, the membranes were
removed with a small scalpel blade, placed on a microscope slide
and coverslipped. The invasion index was then determined by
counting, under a microscope, the total number of stained cells in
the underside of the polycarbonate membranes. In a pilot study, it
was determined that the rate of MDA-MB-231 cell proliferation is
similar at 1% vs. 20% O.sub.2 for at least 48 h, thereby indicating
that differences in cell numbers on the membranes at the end of the
invasion assay are reflective of altered invasive ability
alone.
[0089] Alternatively, cells (e.g., HTR-8/SVneo, MDA-MB-231) were
labeled by incubation for 24 h in the presence of 10 .mu.Ci/ml
[.sup.3H]-thymidine. The cells were then harvested, adjusted to a
concentration of 5.0.times.10.sup.5/ml, and 100 .mu.l aliquots
added in triplicate to the upper wells of the invasion chambers.
After a 24-h incubation, cells in the upper and lower compartments
of the chambers were harvested. The invasion index, reflecting the
percentage of added cells which had invaded the Matrigel was
determined by measurement of the radioactivity in the upper and
lower compartments, as well as in the membrane.
[0090] Determination of PA and gelatinase levels in the culture
medium. Concentrations of gelatinase and plasminogen activators in
the conditioned medium of HTR-8/SVneo cells cultured under standard
or hypoxic conditions were compared using gel zymography, as
described (Graham C H, et al., Exp Cell Res 206:204 (1993)). The
concentrations of uPA antigen in these samples were more accurately
measured using a specific uPA ELISA.
[0091] Determination of cell surface PA activity. Cell surface
plasminogen activator (PA) activity was determined using a
modification of the fluorometric assay of Ellis et al. J Biol Chem
266:12752 (1991). Briefly, HTR-8/SVneo cells were plated in
quadruplicate wells of a 96-well tissue culture plate, and allowed
to grow to 95% confluency. Following a 24 h incubation under an
atmosphere of either 20% O.sub.2 or 1% O.sub.2, the cells were
washed twice, and further incubated with fresh medium containing
plasminogen and the plasmin peptide substrate, HDVLL-AMC, used at
concentrations of 0.2 .mu.M and 0.5 mM, respectively. Plasmin
generation was assessed by determining the fluorescence within
individual microplate wells 30 min later, using a Perkin Elmer
LS50B Luminescence Spectrophotometer (excitation wavelength 360 nm,
emission wavelength 460 nm).
[0092] Zymographic analysis of secreted and cell-associated
plasminogen activators. To examine the levels of secreted
plasminogen activators, serum-free media (EX-CELL 300 medium, JRH
Biosciences, Lenexa, Kans.) conditioned by subconfluent cultures in
35-mm plates incubated under 20% or 1% O.sub.2 for 8, 12, and 24 h
were collected and stored at minus 80.degree. C. After thawing on
ice, volumes containing 200 ng of protein were mixed with SDS
sample buffer and loaded into the wells of an SDS/polyacrylamide
gel containing 2 mg/ml .alpha.-casein and 0.025 units/ml of
plasminogen (Sigma). As a control, parallel samples were loaded
onto gels lacking plasminogen. Following electrophoresis, the gels
were washed twice for 15 min in 2.5% Triton X-100 (Sigma) in water,
rinsed briefly with water and incubated overnight in a solution of
50 mM TRIS and 5 mM CaCl.sub.2. To specifically determine the
levels of uPA in the conditioned media, gels were incubated
overnight with 100 mM amiloride in 50 mM TRIS, 5 mM CaCl.sub.2.
Amiloride selectively inhibits uPA but not other plasminogen
activators (Vassalli and Belin, FEBS Lett., 214:187-191 (1987)).
After incubation, gels were stained with 0.4% Coomassie brilliant
blue R-250 in 10% acetic acid/40% methanol and destained in 10%
acetic acid/40% methanol. Gels were dried between sheets of
cellophane on a Savant gel drier (Savant Instruments, Inc.,
Farmingdale, N.Y.).
[0093] To assess the levels of plasminogen activators associated
with cells cultured for 24 h under 20% and 1% O.sub.2, extracts
were prepared by disrupting trypsinized cell pellets with 2% SDS in
Tris-buffered saline (TBS; 10 mM Tris, 0.15 M NaCl, pH 7.5) using a
Polytron homogenizer (Brinkmann Instruments, Rexdale, ON, Canada).
The homogenates were centrifuged at 15,000 g for 15 min to remove
insoluble materials and 100 .mu.g of extracted protein were
analyzed by casein-plasminogen gel zymography as described
above.
[0094] In Situ Hybridization
[0095] Synthesis of cRNA probes. The plasmid pCRII (Invitrogen) was
linearized by digesting two aliquots of 50 .mu.g each for antisense
and sense probes with EcoRV (Gibco BRL) and BamHI (Gibco BRL)
respectively, overnight at 37.degree. C. The DNA was quantified and
brought to a concentration of 200 ng/.mu.l. In vitro transcriptions
were set up on ice with each reaction containing, in order, 1.3
.mu.l nuclease-free water, 4.0 .mu.l 5.times.transcription buffer,
2.0 .mu.l 100 mM DTT, 0.8 .mu.l rRNAsin (Promega), 4.0 .mu.l GAC
mixture (2.5 mM each of GTP, ATP and CTP), 2.4 .mu.l 100 mM UTP,
1.0 .mu.l linearized DNA, 4.0 .mu.l [.sup.35S]-dUTp (1 mCi/80
.mu.l) and 0.5 .mu.l RNA polymerase (SP6 or T7). The reactions were
mixed by pipetting, up and down, centrifuged for 10 sec, and
incubated for 1 h at 37.degree. C. in a water bath. Following
incubation, 1 .mu.l of RQ1 RNase-free DNase (Gibco BRL) was added,
left for 15 min at 37.degree. C. 1 .mu.l of yeast tRNA (Gibco BRL)
was added to the reaction followed by 450 .mu.l
phenol:chloroform:isoamyl alcohol (25:24:1) extraction. Reaction
products were precipitated overnight at -20.degree. C. with 45
.mu.l 3M sodium acetate (pH 5.2) and 900 .mu.l of ice-cold
RNase-free 100% ethanol. The next day, the RNA was pelleted by
centrifugation for 30 min at 14,000 rpm at 4.degree. C., rinsed
with 70% ethanol and vacuum dried. The pellet was resuspended in
500 .mu.l 10% SDS, 0.25 M EDTA (pH 8.0) and 3M sodium acetate (pH
5.2) and precipitated overnight at -20.degree. C. with 100%
ethanol. The RNA was pelleted by centrifugation for 30 min at
14,000 rpm at 4.degree. C. and rinsed with 70% ethanol. The pellet
was resuspended with 200 .mu.l of 20 mM DTT and RNA was subjected
to limited alkaline lysis with 200 .mu.l of 0.2 M carbonate buffer
(pH 10.2) for 30 minutes at 60.degree. C. The reaction was
neutralized with 12 .mu.l of 3M sodium acetate (pH 5.2) and 20
.mu.l 10% glacial acetic acid. The mixture was precipitated with
100% ethanol overnight at -20.degree. C. The final cRNA product was
pelleted by centrifugation, rinsed with 70% ethanol, dissolved in
100 .mu.l TE (pH 8.0) buffer with 20 mM DTT and stored at
-80.degree. C. until use. The quality of the riboprobes was checked
by running 1 .mu.l of final product through an 8% polyacrylamide
gel and exposing the gel to film. Discrete bands indicated
efficient transcription reactions. Incorporation of the radiolabel
was determined by assessing counts from aliquots of 5 .mu.l at
various time points throughout the transcription reaction.
[0096] Pre-hybridization and Post-hybridization. Tissue sections
were deparaffinized in xylene for 5 min, rehydrated in descending
alcohols for 3 min each (100, 90 and 70%) and incubated in 0.2%
Triton-X100 in PBS for 1 h at room temperature, proteinase-K (1
.mu.g/ml) for 30 min at 37.degree. C. and 0.25% acetic anhydride
(Fisher) in triethanolamine (TEA, Sigma) buffer for 10 min at room
temperature. The sections were then incubated with in situ
hybridization buffer containing 0.3 M NaCl, 20 mM Tris (pH 8.0), 1
mM EDTA, 1.times.Denhardt's solution, 500 .mu.g/ml yeast tRNA, 100
.mu.g/ml denatured salmon sperm DNA, 10% dextran sulfate (Fisher),
0.1% SDS, 100 mM dithiothreital (DTT) and 50% formamide at
42.degree. C. for 2 h. The slides were then hybridized with
[.sup.35S]-dUTP labeled antisense or sense cRNA probes at
concentrations of 1.times.10.sup.6 disintigrations/min/ml in
1.times.in situ hybridization buffer for 18 to 24 hours at
55.degree. C. Glass coverslips (Fisher) were removed by incubation
in 2.times.SSC and tissue sections were then washed in 2.times.SSC,
10 mM DTT at room temperature for 3 min followed by 10 min wash at
55.degree. C. in in situ hybridization buffer. The sections were
treated with RNase A (0.4 mg/ml RNase A (Sigma) in 0.5 M NaCl, 10
mM Tris (pH 8.0), 1 mM EDTA (pH 8.0)) for 30 min at 37.degree.
C.
[0097] Post-hybridization washes consisted of 2.times.SSC with 1M
DTT for 5, 10 and 15 min each at room temperature followed by 4-30
min washes in 2.times.SSC with 1 M DTT at 55.degree. C. and 2-15
min washes in 0.1.times.SSC at 55.degree. C. The slides were
dehydrated in ascending alcohols (70, 90 and 100% ethanol) and for
estimation of exposure times, they were exposed to X-Omat AR film
at -70.degree. C. for 18-24 h. The sections were then dipped in
photoemulsion (NBT-2 nuclear track emulsion, Kodak Laboratories,
Rochester, N.Y.) and exposed at 4.degree. C. for 21-30 days. The
photoemulsion was developed with a D-19 developer, fixed, stained
with hematoxylin and eosin, and mounted with mounting medium. The
slides were viewed under a light microscope and specificity of in
situ hybridization signal was demonstrated by comparing identical
slides radiolabeled with sense cRNA probes.
EXAMPLE 1
[0098] Up-regulation of urokinase-type plasminogen activator
receptor (uPAR) in cancer cells by hypoxia has been demonstrated in
vitro (Graham, C. H., et al., Proc. Amer. Assoc. Cancer Res.,
39:297 (1998)). Compared with standard conditions (20% O.sub.2),
cells cultured for 24 hours under 1% O.sub.2 exhibited a 28%
increase in cell-surface uPAR protein and a 4.5-fold increase in
uPAR mRNA levels, as determined by flow cytometry and Northern blot
analysis. Cells cultured for 24 hours under standard conditions
with 100 .mu.M cobalt chloride also exhibited elevated uPAR protein
and mRNA levels, suggesting that hypoxia stimulates uPAR expression
through a heme protein. Similar effects on uPAR mRNA were obtained
when tumor cells were cultured with sodium
4,5-dihydroxy-benzene-1,3-disulfonate (Tiron), an iron-chelating
agent. These results suggest that hypoxia may contributed to
malignant progression by stimulating uPAR expression on cancer
cells.
EXAMPLE 2
[0099] In vitro studies were undertaken to determine whether
hypoxia, similar to that which occurs naturally in, for example,
the first trimester placenta and hypoxic tumors, affects
plasminogen activator inhibitor-1 (PAI-1) expression. These studies
show that hypoxia up-regulates PAI-1, high levels of which
correlate with a poor prognosis in some cancer patients. Culture
Under Hypoxia for 24 hours Does Not Affect Viability of Trophoblast
Cells.
[0100] Before examining the effects of hypoxia on expression of
PAI-1 by the HTR8/SVneo trophoblast cells, it was necessary to
verify whether they could tolerate prolonged periods of low oxygen
without significant effect on their viability. No detectable
variations in cell morphology could be seen at the light
microscopic level between cells cultured under standard conditions
and those cultured under 1% oxygen for a duration of 24 hours. The
viability of these cells was further assessed by measuring lactate
dehydrogenase (LDH) levels in the medium collected from both
culture conditions. Two independent experiments, each performed in
triplicate, could not detect significant differences in LDH
accumulation (Table 1). Similarly, cultures exposed to 8, 12 and 24
hours of hypoxia did not exhibit reduced cell viability as
determined by trypan blue exclusion (Table 1).
1TABLE 1 Assessment of cell viability as determined by lactate
dehydrogenase (LDH) accumulation and trypan blue exclusion P
(Student's 20% Oxygen 1% Oxygen t-Test) LDH levels 24 h 163.4 .+-.
7.0 145.6 .+-. 5.0 0.26 (U/ml) Trypan blue 8 h 89.1% .+-. 5.0%
87.5% .+-. 2.0% 0.46 exclusion 12 h 85.4% .+-. 0.5% 83.7% .+-. 5.0%
0.80 24 h 88.7% .+-. 2.0% 91.8% .+-. 0.1% 0.30 Hypoxia Increases
the Levels of PAI-1 mRNA Through a Mechanism That Involves a Heme
Protein.
[0101] The effect of hypoxia on the expression of PAI-1 by human
first trimester trophoblast cells (HTR-8/SVneo) was demonstrated at
the mRNA level by Northern blot analysis. Progressive
time-dependent increases in PAI-1 mRNA (both the 3.0- and 2.3 kb
PAI-1 transcripts) were observed in cells cultured under 1%
O.sub.2. This hypoxia-mediated stimulation of PAI-1 transcripts was
evident as early as 2 hours, was elevated about 6-fold from 4 to 12
hours, and about 16- and 32-fold (for the 3.0- and 2.3-kb
transcript species respectively) at the 24 hour point.
[0102] To assess the possible involvement of a heme protein in the
regulation of PAI-1 expression by hypoxia, HTR-8/SVneo cells were
cultured for 24 hours in the presence of chemicals such as cobalt
chloride and Tiron, which prevent binding of molecular oxygen to
heme proteins and thus mimic hypoxia, as well as under hypoxia in
the presence or absence of 20% carbon monoxide. Culture under 1%
oxygen or in the presence of the iron chelator, Tiron, resulted in
a substantial increase in the levels of both the 3.0-kb and the
2.3-kb and the 2.3-kb PAI-1 transcripts. Similarly, culture in the
presence of cobalt chloride produced an increase of about 2-fold,
whereas inclusion of 20% carbon monoxide in the hypoxic environment
prevented most of the hypoxia-mediated increase in PAM-1 mRNA
levels. These finding demonstrate that hypoxia up-regulates PAI-1
expression at the mRNA level in first trimester invasive
trophoblast cells and that this effect is mediated through a heme
protein-dependent mechanism. Hypoxia increase the levels of PAI-1
in Culture Medium
[0103] ELISA measurements performed in duplicate demonstrated a
consistent increase in plasminogen activator inhibitor-1 levels in
the condition medium of HTR-8/SVneo cells cultured under 1% oxygen,
beginning at 4 hours and continuing at 8, 12 and 24 hours, compared
with 20% oxygen (Table 2). Although no stimulation in PAI-1 protein
secretion was observed at less than 2 hours of hypoxic exposure,
the PAI-1 levels were nearly two-fold higher in the hypoxia versus
the normoxia group as early as the 8 hour time point.
2TABLE 2 Measurement of PAI-1 levels in the culture medium of
HTR-8/SVneo cells by ELISA 20% Oxygen 1% Oxygen Percent (ng/ml)
(ng/ml) Change Experiment 1 24 h 2.054 3.414 66 Experiment 2 24 h
8.995 9.233 3 Experiment 3 24 h 5.580 12.384 122 12 h 5.725 9.745
70 8 h 3.567 6.107 70 Experiment 4 12 h 5.567 8.192 47 8 h 7.721
11.131 44 4 h 12.851 13.106 2 Experiment 5 8 h 2.299 4.760 107 2 h
1.218 0.266 78 1 h 0.437 Undetectable 30 min Undetectable
Undetectable
[0104] Adhesion of HTR-8/SVneo Cells to the ECM Protein Vitronectin
Is Markedly Reduced by Hypoxia
[0105] Since PAI-1 has been shown to modulate cell adhesion through
its interaction with the ECM protein vitronectin, the effect of
hypoxia on the adhesive properties of the human trophoblast cell
line HTR-8/SVneo was examined. Adhesion of these cells to
vitronectin-coated wells was reduced by approximately 60% when the
adhesion assay was conducted under a hypoxic environment with cells
that had been previously maintained under hypoxia for 24 hours.
Interestingly, the cells' adhesiveness was restored to about 80% of
standard levels following re-exposure of the cells to 20% oxygen
for a duration of 30 minutes and throughout the adhesion period (45
minutes).
[0106] These studies indicate that culture under low levels of
oxygen results in up-regulation of PAI-1 expression at the protein
and mRNA levels in first trimester invasive trophoblast cells and
that this effect is mediated through a heme protein-dependent
mechanism. This conclusion is based on observations in which
chemicals that prevent binding of oxygen to heme proteins, such as
cobalt chloride and Tiron, were able to mimic hypoxia and by the
fact that inclusion of carbon monoxide in the hypoxic atmosphere
abolished the effect of hypoxia on PAI-1 mRNA levels.
EXAMPLE 3
[0107] Identification of RTP/Drg1 Gene Induced by Hypoxia by mRNA
Differential Display
[0108] The mRNA differential display technique (Liang, P. and
Pardee, A. B. Science 257:967-971 (1992)) was used to compare gene
expression in cells cultured under 1% oxygen or 20% oxygen. Each
experiment was performed in triplicate to assure reproducibility. A
representative autoradiogram obtained by differential display
analysis of MDA-MB-231 cells cultured under 20% oxygen and 1%
oxygen is shown in FIG. 1. cDNA bands exhibiting differential
intensities were excised from the gels, cloned, and used as probes
for Northern blotting.
[0109] One particular clone appeared to be markedly up-regulated in
all gels examined. Upon sequence analysis, the isolated 312-bp cDNA
fragment displayed 100% similarity to a gene previously identified
by three separate groups, termed RTP (reducing agents and
tunicamycin-responsive protein) (Kokame, K., et al., J Biol Chem
271:29659-29665 (1996)), Drg1 (differentiation-related gene 1) (van
Belzen, N., et al., Lab Invest 77:85-92 (1997)), and Cap43 (Zhou,
D., et al., Cancer Res 58:2182-2189 (1998)). Furthermore, the full
cDNA sequence of the gene has been resolved and found to consist of
3056 bp (Kokame, K., et al., J Biol Chem 271:29659-29665 (1996)).
Effect of Exposure to Hypoxia on RTP/Drg1 mRNA Levels.
[0110] Northern blot analysis revealed that, following hypoxic
culture, the levels of RTP/Drg1 mRNA were substantially increased
(over 16-fold) in the HTR-8/SVneo trophoblast cells, the MDA-MB-231
and MCF10A1T3B breast carcinoma cells, and in the human aortic
smooth muscle cells (FIG. 2A). The induction of RTP/Drg1 mRNA in
MDA-MB-231 cells was first apparent after 8 h of exposure to
hypoxia, reached a maximum at 24 h, and remained high for at least
60 h (FIG. 2B). Viability of the MDA-MB-231 cells incubated under
1% oxygen, as assessed by trypan blue exclusion and LDH
accumulation, also remained high for at least 48 h (data not
shown). Following a 24-h incubation of MDA-MB-231 cells under 1%
oxygen, a 2-h re-exposure to standard (20% oxygen) conditions was
sufficient to substantially reduce RTP/Drg1 mRNA levels (FIG. 2C).
Oxygen dose-dependent response analysis revealed markedly increased
RTP/Drg1 mRNA levels in cells cultured under 1% or 2% oxygen for 24
h (16- and 10-fold respectively; FIG. 2D). In contrast, compared
with culture under 20% oxygen, culture under 4% oxygen did not
result in increased RTP/Drg1 transcript levels (FIG. 2D).
[0111] Expression of RTP/Drg1 Protein
[0112] The anti-Drg1 antiserum recognized a protein of the expected
43-kDa size in Western blots. Increase in RTP/Drg1 protein was
first apparent in MDA-MB-231 cells following 8 h culture under 1%
oxygen (FIG. 3A). However, the highest levels of the 43-kDa protein
were observed in cells cultured under 1% oxygen for at least 24 h
(FIG. 3A). Although incubation for 24 h under 4% oxygen resulted in
increased levels of protein, the highest levels were observed in
cells cultured under 1% or 2% oxygen FIG. 3B). In contrast to
RTP/Drg1 mRNA levels, which reversed to control values soon after
re-exposure to higher oxygen levels, reoxygenation did not result
in any substantial drop in the levels of the 43-kDa protein for at
least 12 h (FIG. 3C).
[0113] To further investigate the role of hypoxia on the expression
of RTP/Drg1 protein, three-dimensional aggregates of HTR-8/SVneo
trophoblast and MDA-MB-231 breast carcinoma cells as models of
tissue hypoxia were used. It is recognized that oxygen gradients
exist between superficial and deeper layers of multicellular
spheroids, with the innermost layers being more hypoxic (Waleh, N.
S., et al., Cancer Res 55:6222-6226 (1995); Sutherland, R. M., et
al., Cancer Res 46:5320-5329 (1986)). Spheroids cultured under
standard (20% oxygen) conditions exhibited nuclear and cytoplasmic
RTP/Drg1 protein immunolocalization in cells within the deeper
hypoxic layers, while cells in the more superficial layers remained
unlabeled. In contrast, RTP/Drg1 staining was observed throughout
entire aggregates, including the cells in the superficial layers,
when spheroids were incubated for 24 h under 1% oxygen. Similar
staining patterns were observed in MDA-MB-231 spheroids cultured
under 20% and 1% oxygen (data not shown).
[0114] Role of a Heme Protein in the Hypoxic Regulation of RTP/Drg1
Expression
[0115] If certain hypoxic responses are mediated through a putative
iron-containing heme protein, the deoxy conformation of such
protein can be maintained by replacing the iron atom within the
porphyrin ring of the heme moiety with metals that do not bind
oxygen or do so with very low affinity, such as cobalt, or by
chelating iron with compounds such as Tiron or desferrioxamine
(DFO). Culture of MDA-MB-231 cells for up to 72 h, under 20%
oxygen, with 100 .mu.M cobalt chloride, 30 mM Tiron, or 100 .mu.M
DFO resulted in time-dependent increases in RTP/Drg1 protein (FIG.
4A) and mRNA (FIG. 4B). Furthermore, presence of 30% carbon
monoxide in the hypoxic atmosphere abrogated the hypoxic
up-regulation of RTP/Drg1 mRNA (FIG. 5A) and protein (FIG. 5B).
Like oxygen, carbon monoxide binds to heme proteins and maintains
them in the oxy conformation, thereby blocking heme
protein-mediated hypoxic responses. To rule out the possibility
that the inhibition of the hypoxic effect by carbon monoxide was
not due to non-specific toxicity on the cells, we cultured
MDA-MB-231 cells with cobalt chloride, Tiron and DFO under hypoxic
conditions in the presence of carbon monoxide. Western and Northern
blot analysis revealed that the presence of carbon monoxide in the
atmosphere did not inhibit the up-regulation of RTP/Drg1 expression
induced by cobalt chloride, Tiron and DFO (FIGS. 5A and 5B).
RTP/DRG1 message is elevated in preeclamptic placental tissues.
[0116] RTP/Drg1 message levels were measured in placental tissues
from normal pregnancy and preeclampsia by northern blot analysis
(FIG. 6). Levels of message are indicated by the intensity of the
bands. CV=chorionic villi, BPD=basal plate decidua, MD=membrane
decidua, A=amnion (amnniotic membrane). Note higher intensity in
the RTP-Drg1 bands in tissues isolated from preeclamptic
pregnancies. Expression pattern of RTP/Drg1 (PROXY-1) message in
placental tissue.
[0117] The expression pattern of RTP/Drg1 (PROXY-1) message was
analyzed by in situ hybridization analysis of placental tissue
sections. Antisense or sense (negative control) radiolabelled
RTP/Drg1 cRNA probes (riboprobes) were incubated with placental
chorionic villi or placental membranes (decidua and chorion)
isolated from women with either normal pregnancies or preeclampsia
at full term of gestation. Hybridization reactions were detected by
the presence of grains in the photographic emulsion (white dots in
dark-field images). A higher number of hybridization grains were
detected in tissues isolated from preeclamptic pregnancies as
compared with normal tissues. Hybridization grains were observed
overlying all cell types present in the tissues, indicating that
all of the cell types in these tissues are capable of expressing
RTP/Drg1 message. Relatively few hybridization grains were detected
in sections incubated with sense probe (negative controls: should
not hybridize with RTP/Drg1 message) and indicate background. These
results suggest that placental tissues from preeclamptic
pregnancies are exposed to lower levels of oxygen than similar
tissues isolated from normal pregnancies (FIGS. 25A-25D, and data
not shown).
EXAMPLE 4
[0118] Urokinase Receptor Expression is Stimulated by Hypoxia
[0119] The effect of hypoxia on the expression of uPAR by
HTR-8/Svneo cells (FIG. 7) was determined. In comparison to cells
cultured under standard conditions (20% O.sub.2), the expression of
uPAR by cells cultured in 1% O.sub.2 for 24 h was 68% higher (n=7,
P=0.007), as determined by flow cytometry. Equal amounts of
non-immune mouse IgG.sub.2a bound to cells cultured under both
standard and hypoxic conditions, demonstrating that increased
binding of anti-uPAR mAb 3937 was not due to non-specific
interactions, or increased Fc.gamma. receptor expression.
Similarly, assessment of uPAR expression by HTR-8/SVneo cells
through measurement of [.sup.125I]-prourokinase binding revealed
that hypoxia stimulated the expression of uPAR by 88% (n=9,
P=0.003), an increment similar to that detected using flow
cytometry. This was accompanied by a parallel increase in the
K.sub.d (Table 3), as well as by an increase in the cellular
content of uPAR mRNA (FIG. 8). Increased uPAR mRNA expression was
first apparent after 4 h of exposure to hypoxia, and reached a
maximum level after 6 h.
[0120] It has been reported that VEGF increases the expression of
uPAR by vascular endothelial cells (Mandriota S J, et al., J Biol
Chem 270:9709 (1995)). Furthermore, recent studies have shown that
hypoxia stimulates VEGF release by increasing transcriptional
activation of the VEGF gene via hypoxia-inducible factor-1 (HIF-1)
as well as through mRNA stabilization (Shweiki D, et al., Proc Natl
Acad Sci USA 92:768 (1995), Minchenko A, et al. Lab Invest 71:374
(1994), Forsythe J A, et al, Mol Cell Biol 16:4604 (1996), White F
C, et al. Growth Factors 12:289 (1995). In the present study,
however, culture of HTR-8/SVneo cells in the presence of 10 ng/ml
of VEGF for 24 h under normoxic conditions did not result in
increased levels of uPAR transcript above control values (FIG. 9),
suggesting that the hypoxia-mediated upregulation of uPAR occurs
through a VEGF-independent mechanism.
[0121] Whether the effects of hypoxia on uPAR expression extended
to other cell types such as endothelial cells was investigated.
FIG. 10 shows results in which similar effects of hypoxia on
up-regulation of uPAR expression were detected by radioligand
binding studies using human umbilical vein endothelial cells. These
results were also confirmed by flow cytometry (not shown).
3TABLE 3 Effects of hypoxia, Tiron and cobalt chloride on the
binding of [.sup.125I]-prourokinase to HTR-8/SVneo cells B.sub.max
(sites/cell) .+-. K.sub.d (nM) .+-. P P Condition SEM SEM
(B.sub.max) (K.sub.d) n Standard vs. Hypoxia: Standard 189,028 .+-.
39,222 1.26 .+-. 0.16 9 Hypoxia 356,728 .+-. 64,488 2.18 .+-. 0.42
0.003 0.025 9 Standard vs. Tiron: Standard 208,980 .+-. 26,825 2.93
.+-. 0.59 6 Tiron 623,213 .+-. 102,360 8.08 .+-. 1.11 0.004 0.001 6
Standard vs. Cobalt Chloride: Standard 223,026 .+-. 37,035 2.49
.+-. 0.47 8 Cobalt 285,711 .+-. 38,324 3.58 .+-. 0.69 0.014 0.004 8
Chloride
[0122] Role of a Heme Protein in the Regulation of uPAR
Expression
[0123] To examine the potential involvement of a heme protein in
the hypoxia-mediated stimulation of uPAR expression, the expression
of uPAR by HTR-8/SVneo cells in response to incubation in the
presence of cobalt chloride or Tiron was examined. Both flow
cytometric and radioligand binding studies revealed a 3-fold
increase in the expression of uPAR in response to Tiron (n=6,
P=0.004), with a more modest 28% increase observed in response to
cobalt chloride (n=8, P=0.014; Table 3). In each case, the K.sub.d
increased as well, as observed following exposure of cells to
hypoxia. Stimulation of uPAR expression by either cobalt or Tiron
was associated with increased levels of uPAR mRNA, comparable to
those observed in response to hypoxia (FIG. 11).
[0124] To further assess the potential role of a heme protein in
the increased expression of uPAR in response to hypoxia, we
assessed the effects of carbon monoxide on this response. As
expected, increased uPAR expression following culture of
HTR-8/SVneo cells under hypoxic (1% oxygen) conditions was
inhibited (56%) by inclusion of 20% carbon monoxide in the gas
mixture (FIG. 12); a parallel decrease was observed in the content
of cellular uPAR mRNA (FIG. 11). Furthermore, in two independent
experiments, the inhibitory effects of carbon monoxide on the
hypoxia-induced expression of uPAR were completely prevented by
inclusion of cobalt chloride or Tiron in the medium (not shown),
demonstrating that the inhibition of uPAR expression by CO under
hypoxic conditions was not due to nonspecific toxicity. Hypoxia
stimulates in vitro invasiveness via a heme protein.
[0125] To determine the functional correlates of hypoxia-induced
uPAR expression, the invasion of HTR-8/SVneo cells through a
reconstituted basement membrane (Matrigel) under standard (20%
oxygen) and hypoxic (1% oxygen) conditions were compared. A
41.4%.+-.7.4% (P=0.003) increase in invasion was observed when
HTR-8/SVneo cells was were cultured under hypoxic conditions (Table
4). Similar increases were observed when invasion assays were
performed under 20% oxygen in the presence of either 100 .mu.M
cobalt chloride (24.6.+-.8.4%; P=0.028) or 30 mM Tiron
(29.3.+-.12.7%; P=0.035) (Table 4). The role of a heme protein in
the regulation of cellular invasiveness was confirmed by
experiments in which hypoxia-stimulated invasion was inhibited by
87% in the presence of 20% carbon monoxide, and was not
significantly different from that which occurred in the presence of
20% oxygen (Table 4).
4TABLE 4 Effects of hypoxia, carbon monoxide, Tiron and cobalt
chloride on invasion of HTR-8/SVneo cells through Matrigel
Condition Invasion Index* (%) .+-. SE P (vs standard) n Standard
(20% O.sub.2) 100 11 Hypoxia (1% O.sub.2) 141.4 .+-. 7.4 0.003 11
Standard + Cobalt 124.6 .+-. 8.4 0.028 9 Chloride Standard + Tiron
129.3 .+-. 12.7 0.035 6 Hypoxia + 20% CO 104.0 .+-. 8.5 0.684 10
*The invasion index was calculated as described (Graham CH, et al.,
Exp Cell Res 206:204 (1993)).
[0126] Effect of Hypoxia on PA and Gelatinase Levels in Culture
Medium, and on Cell Surface Plasminogen Activator Activity
[0127] Gel zymography revealed a time-dependent reduction in the
levels of plasminogen activators in medium conditioned by
HTR-8/SVneo cells cultured for up to 24 h under 1% O.sub.2 (FIG.
13). These observations were supported by additional studies in
which direct measurement of urokinase antigen levels in the
conditioned medium of HTR-8/SVneo cells cultured under hypoxic
conditions for 24 h were reduced by a mean of 52%. In contrast, the
expression of cell surface plasminogen activator activity by
HTR-8/SVneo cells cultured for 24 h under hypoxic conditions was
20% higher than that expressed by cells cultured under standard
conditions (P=0.000007). These findings are consistent with binding
of secreted urokinase to increased numbers of cellular uPAR.
[0128] Additional studies in which the levels of gelatinases in the
conditioned medium of HTR-8/SVneo cells cultured under standard or
hypoxic conditions were assessed by gelatin zymography revealed
that hypoxia did not affect the amounts of these proteins released
in response to hypoxia (not shown). These observations suggest that
the increased invasiveness of HTR-8/Svneo cells observed under
hypoxic conditions is not attributable to the increased production
or secretion of these proteinases, and instead results from other
mechanism, potentially involving increased expression of uPAR.
EXAMPLE 5
[0129] Effect of Exposure to Hypoxia on Cell Surface Levels of
uPAR
[0130] Compared with culture under standard conditions, culture of
MDA-MB-231 cells in 1% O.sub.2 for 24 h resulted in a 54% increase
in uPAR levels as determined by flow cytometry (FIG. 14).
Interestingly, culture under 4% O.sub.2 also resulted in increased
cell surface uPAR levels as compared with culture under 20%
O.sub.2. However, these levels were 30% lower than those observed
in cells cultured under 1% O.sub.2 (FIG. 14). A similar increase
(30%, N=3) in uPAR levels was observed in YR-A small cell lung
carcinoma cells when cultured under 1% O.sub.2 for the same length
of time, while a more moderate increase (9%, N=2) was obtained in
the MCF-10AT3B cells.
[0131] Whether an iron-containing heme protein is involved in the
regulation of cell surface uPAR expression was examined. Therefore,
MDA-MB-231 cells were cultured for 24 h in the presence or absence
of 100 .mu.M cobalt chloride under standard (20% O.sub.2)
conditions. Binding of oxygen to the iron atom in the porphyrin
ring of heme proteins induces conformational changes from the
deoxy, or tense, to the oxy or relaxed state. The deoxy
conformation of heme proteins can initiate signaling pathways that
lead to increased transcription of hypoxia-regulated genes. In
addition to hypoxia, the deoxy (active) conformation can be
maintained by substituting the iron molecule within the porphyrin
ring with elements like cobalt, that either do not bind oxygen or
do so with low affinity, or by culturing cells with iron chelating
agents, such as sodium 4,5-dihydroxybenzene-1,3-disulfonate (Tiron)
or desferrioxamine. In this study, culture of MDA-MB-231 cells in
the presence of cobalt chloride for 24 h resulted in an increase in
surface uPAR levels (FIG. 15).
[0132] Effect of Hypoxia, Cobalt Chloride, Tiron and Carbon
Monoxide on uPAR mRNA Levels
[0133] To determine whether the hypoxia-mediated increases in cell
surface uPAR expression reflected changes in uPAR mRNA levels,
tumorigenic breast MCF-10AT3B and tumorigenic and metastatic
MDA-MB-231 carcinoma cells were cultured under 1% O.sub.2 for up to
24 h. Compared with culture under standard conditions, culture of
MCF-10AT3B cells for as little as 2 h under hypoxic conditions
resulted in a 2-fold increase in uPAR transcript levels, which
increased by 4-fold in cells cultured for 16 h under hypoxia (FIG.
16). Interestingly, uPAR mRNA levels returned to control values by
24 h of hypoxic culture (FIG. 16). In contrast, uPAR transcript
levels in MDA-MB-231 cells remained unchanged following 2 h of
hypoxic culture but increased by 2-fold after 4 h of hypoxia,
reaching a 5.5-fold increase after 24 h under hypoxia (FIG. 17). If
a putative heme protein is involved in the hypoxia-mediated
increase in uPAR mRNA levels, the oxy or inactive conformation of
this protein can be maintained in hypoxic cells if CO is present in
the hypoxic atmosphere, as this molecule binds to heme proteins and
induces conformational changes in a manner similar to oxygen. In
MDA-MB-231 cells, culture under hypoxic conditions for 24 h in the
presence of 30% CO resulted in lower uPAR mRNA levels than in cells
cultured under hypoxia alone (FIG. 17). Furthermore, culture under
standard (20% O.sub.2) conditions for 24 h in the presence of 100
.mu.M cobalt chloride or 30 mM Tiron also resulted in substantial
increases in uPAR mRNA levels (FIG. 18).
[0134] Secreted and Cell-associated Plasminogen Activators
[0135] Zymographic analysis of serum-free medium conditioned by
MDA-MB-231 cells for 8, 12 and 24 h under standard or hypoxic
culture conditions revealed caseinolytic bands at approximately
50-55 kDa (FIG. 19A). The intensity of these bands was lower in the
medium conditioned by cells cultured under hypoxia at all time
points examined. By incubating the gels overnight with 100 mM
amiloride, these caseinolytic bands were abolished (FIG. 19B),
indicating that they represent uPA activity. If the reduction in
free UPA in the culture media of cells incubated under hypoxia was
due to increased binding of secreted pro-uPA to newly available
uPAR, then an increased levels of cell-associated uPA would result.
When extracts of cells were assessed by casein-plasminogen gel
zymography, an increase in uPA levels was observed in cells
cultured under 1% vs. 20% O.sub.2 (FIG. 19C). Consistent with the
notion that a heme protein regulates the levels of uPA-binding
sites on the cell surface was the observation that culture with
cobalt chloride resulted in increased cell-associated uPA. Also,
incubation with 30% CO under hypoxic conditions abrogated the
hypoxic increase in cell-associated uPA (FIG. 19C). In a similar
manner as the conditioned media, incubation with amiloride
eliminated the 50-55 kDa caseinolytic activity from cell extracts
(FIG. 19D).
[0136] Effect of Hypoxia on in Vitro Invasiveness
[0137] To determine a functional correlate of increased uPAR levels
in hypoxic cultures, the effect of exposure to low levels of oxygen
on the ability of tumor cells to invade Matrigel in vitro was
assessed. In one series of tests, MDA-MB-231 cells exhibited an
invasion index 40% higher under 1% O.sub.2 than under standard
conditions (p<0.01, Student=s t-test; N=15). This
hypoxia-mediated increase in invasiveness was completely abrogated
by inclusion of 30% CO in the hypoxic atmosphere (not shown),
suggesting also the involvement of a heme protein on the effect of
hypoxia on invasion. Another set of tests were performed to
determine whether the increased invasiveness observed under hypoxia
is directly linked to uPAR upregulation. The inclusion of a
blocking anti-uPAR antibody (3936) with the cells at the initiation
of the invasion assay abolished the effect of hypoxia on invasion
(FIG. 20). The presence of this antibody also resulted in a 65%
reduction in the invasiveness of cells incubated under standard
conditions, suggesting that functional uPAR is required for basal
levels of invasion.
[0138] Discussion
[0139] The results of this study demonstrate the up-regulated
expression of genes (uPAR, PAI-1 and RTP/Drg1 ) in various cell
types cultured under low levels of oxygen. The expression of
RTP/Drg1 has also been shown to be increased in endothelial cells
treated with homocysteine (Kokame, K., et al. J Biol Chem
271:29659-29665 (1996)) as well as during differentiation of colon
epithelial cells (van Belzen, N., et al. Lab Invest 77:85-92
(1997)) and in human lung A549 cells exposed to nickel (Zhou, D.,
et al., Cancer Res 58:2182-2189 (1998)).
[0140] RTP/Drg1 , uPAR and PAI-1 can be added to the growing list
of oxygen-regulated genes of mammalian cells which include those
encoding key enzymes of the glycolytic pathway (Semenza, G. L., et
al., J.Biol.Chem 269:23757-23763 (1994)), erythropoietin (Goldberg,
M. A., et al., Science 242:1412-1415 (1988)), vascular endothelial
growth factor (VEGF) (Forsythe, J. A., et al., Mol.Cell.Biol.
16:4604-4613 (1996)) and heme oxygenase-1 (Lee, P. J., et al., J
Biol Chem 272:5375-5381 (1997)) among several. The mechanism by
which hypoxia stimulates expression of some of the above genes
appears to involve transcriptional activation by nuclear factors
such as hypoxia inducible factor-1 (HIF-1) (Forsythe, J. A., et
al., Mol.Cell.Biol. 16:4604-4613 (1996)), AP-1 and NF-.kappa.B
(Rupec, R. A. and Baeuerle, P. A. Eur.J.Biochem. 234:632-640
(1995)). HIF-1 is a heterodimeric protein, composed of a
HIF-1.alpha. and a HIF-1.beta. subunit, first identified as a
DNA-binding activity that recognized a DNA sequence in the
hypoxia-inducible enhancer of the erythropoietin gene (Semenza, G.
L. and Wang, G. L. Mol.Cell.Biol. 12:5447-5454 (1992)). More recent
studies have revealed that HIF-1 plays an important role in the
hypoxia-mediated inhibition of cellular proliferation and induction
of apoptosis (Carmeliet, P., et al., Nature 394:485-490 (1998)).
Elucidation of the sequences flanking the gene, can determine
whether HIF-1 and/or other transcription factors are involved in
the hypoxic up-regulation of RTP/Drg1 expression.
[0141] The results of this study suggest that the hypoxic
up-regulation of uPAR, PAI-1 and RTP/Drg1 is mediated through an
oxygen-sensing heme protein. This conclusion is based on the
results of experiments in which the ability of such a protein to
regulate uPAR, PAI-1 or RTP/Drg1 expression was evaluated through
the use of molecules like cobalt chloride, Tiron and DFO, which
mimic hypoxia by preventing the binding of oxygen to the heme
moiety of the putative oxygen-sensing protein (cobalt), or by
blocking heme biosynthesis (Tiron and DFO). The fact that
incubation with these three compounds led to similar observations
suggests that the results were due to inhibition of a
heme-containing protein and not due to non-specific effects.
Furthermore, we also showed that the up-regulation of uPAR, PAI-1
and RTP/Drg1 expression in response to hypoxia was blocked by
carbon monoxide. Since carbon monoxide was unable to inhibit the
up-regulation of RTP/Drg1 expression induced by cobalt chloride,
Tiron and DFO, it indicates that its effect was not due to
non-specific toxicity. Interestingly, when the RTP/Drg1 gene was
cloned independently by Zhou et al (Zhou, D., et al., Cancer Res
58:2182-2189 (1998)) (named Cap43 by these investigators), it was
found to be induced by nickel, a molecule that also replaces
ferrous iron from heme proteins and which does not bind oxygen. It
is possible that, in their study, the up-regulation of RTP/Drg1 in
lung epithelial cells in response to nickel exposure was due to the
heme protein-blocking properties of nickel and not due to its
carcinogenic effects.
[0142] The described study also revealed that the 43-kDa protein
encoded by the RTP/Drg1 gene localizes to the hypoxic, deeper
regions of multicellular spheroids cultured under 20% oxygen.
However, culture of cell aggregates under 1% oxygen resulted in
widespread immunolocalization of the protein, even in the
superficial layers of the spheroids. Three-dimensional cell
cultures have been used extensively to study the role of oxygen
levels in various aspects of tumour biology including sensitivity
to chemotherapy and radiation, metabolism, invasion and metastasis,
and angiogenesis (Mueller-Klieser, W. Am J Physiol 273:C1109-C1123
(1997)). Since low intratumoral oxygen levels are associated with a
poor clinical prognosis (Brizel, D. M., et al., Int. Radiation
Oncology Biol.Phys. 38:285-289 (1997); Hockel, M., et al., Cancer
Res. 56:4509-4515 (1996); Brizel, D. M., et al., Cancer Res.
56:941-943 (1996)), the 43-kDa protein described in our study may
be a good marker of hypoxic regions within the tumor mass and
therefore of prognostic significance.
[0143] The present findings demonstrated substantially increased
RTP/Drg1 expression in cells incubated under 1% and 2% oxygen
compared to cells cultured at or above 4% oxygen. These results may
be of physiologic and clinical relevance, as most tissues in the
body are exposed to oxygen concentrations equivalent to 5% or
lower. This study also showed that the high levels of expression of
RTP/Drg1 protein persisted for at least 72 h following a hypoxic
stimulus, indicating a relatively slow turnover of this protein. In
contrast, the increased expression of cell surface urokinase
receptors in response to hypoxia returns to background levels about
45 minutes following reoxygenation. The fact that cellular RTP/Drg1
expression remains high for an extended period following transient
exposure to low levels of oxygen may also be relevant to conditions
in which relatively short periods of exposure to hypoxia occur,
such as during temporary vasoconstriction, sleep apnea, or fetal
hypoxia. The described findings suggest that such episodes of
hypoxia may lead to long-lasting phenotypic changes. Since our
results show an inverse correlation between oxygen concentration
and RTP/Drg1 expression, assessment of the levels of this protein
may be useful in determining the extent of oxygen deprivation in
the above settings. Our data reveal increased RTP/Drg1 mRNA levels
in hypoxic, peri-infarct regions of placentae of preeclamptic women
compared to non-infarct areas or normal placentae.
EXAMPLE 6
[0144] Materials and Methods
[0145] Animals
[0146] 16 adult male Wistar rats from Charles River Laboratories
(Montreal, Quebec) weighing 300-350 g were used in the
investigation. The animals were divided into two study groups. The
animals were individually housed in a climate-controlled room under
a 12-hour light/dark cycle and allowed access to food (Purina Lab
Chow) and water ad libitum. All procedures were in accordance with
the guidelines set out by the Canadian Council on Animal Care. The
animals were allowed to acclimate 5 days prior to testing and were
handled by the researcher during this time.
[0147] Experimental Procedure
[0148] The apomorphine (APO) bioassay of erectile function was
performed in an isolated area. The rat model of APO-induced
erections used to assess the effects of p,p-DDE and flatamide on
erectile function was based on the model developed by Heaton et at
J. Urol. 145:1099 (1991). The animals were each placed in a
separate hanging wire test cage in an isolated, dark and sound
proof room and allowed to acclimatize to the surroundings for 10
minutes. Each rat received 80 ug/kg APO (Sigma Chemical Co., St.
Louis, Mo.) prepared in physiological saline containing 100 ug/kg
ascorbic acid via subcutaneous (s.c.) injection (1 ml/kg at the
nape of the neck). Erectile and yawning responses to APO were
monitored and recorded (30 minutes) in an adjacent room via a video
monitoring system.
[0149] An erection was counted when an engorged glans penis and
distal shaft were exposed. A wide opening of the mouth associated
with appropriate respiratory movement identified a yawn. Prior to
the commencement of each study, each group of eight rats were
pre-tested with APO to ensure that each rat had a normal `control`
erectile response. Rats with unsatisfactory control erectile
response were removed from further study.
[0150] In order to develop a suitable APO-testing protocol during
the p,p-DDE treatments, two different time series of
administrations were used in preliminary experiments (n=6 rats).
Series 1 involved APO-treatments at 7 time points (0.5, 3, 5, 7,
12, 24, 48 hours) over 2 days. In Series 2, performed 3-4 weeks
later, we used only 5 time points (0.5, 4, 12, 24, 48 hours) over 2
days. The results of this methodological study (FIG. 21) clearly
revealed that the Series 2 protocol of APO administrations provided
a more reproducible means of testing erectile responses. The more
frequent Series 1 protocol showed a persistent decrease in erectile
responses over the time course. Yawns were not altered in either
protocol (data not shown). Based on the results of this study all
subsequent time course testing used the Series 2 time course (0.5,
4, 12, 24, 48 hours).
[0151] Study 1: Preliminary Assessment of p,p-DDE Effects
[0152] The doses of p,p-DDE were derived from the literature.
According to Gray et al Physiol. & Behav. 24:463 (1980), daily
subcutaneous administration of flutamide (25 mg/kg) caused a
significant decrease in erections. As shown by Kelce et al, p,p-DDE
has approximately one tenth the affinity for androgen receptors
compared to flutamide Kelce et al Nature. 375:581 (1995).
Accordingly, based on the studies by Gray et al and Kelce et al the
initial dose of p,p-DDE (270 mg/kg) was calculated to provide a
equi-effective dose compared to flutamide (25 m/kg).
[0153] Six rats were each administered on separate occasions a
single dose of 270 mg/kg or 500 mg/kg p,p-DDE (Aldrich Chemical
Co., Milwaukee, Wis.) dissolved in peanut oil. The 270 mg/kg dose
was prepared, requiring initial heating and stirring. This dose was
administered in a single injection (1 ml/kg, i.p. of a 270 mg/ml
concentration) half an hour prior to the commencement of
APO-induced erectile monitoring. The second dose of p,p-DDE (500
mg/kg) was administered one week after the initial dose of 270
mg/kg. The 500 mg/kg dose of p,p-DDE was prepared in a 250 mg/ml
concentration and administered in a single injection (2 ml/kg i.p.)
half an hour prior to the commencement of APO-induced erectile
monitoring.
[0154] Study 2a: Flutamide Administration
[0155] Eight rats were treated with APO to determine baseline
erectile and yawning response. The following day, rats were subject
to a control series of APO tests at intervals of 0.5, 4, 12, 24, 48
hours after a starting time.
[0156] At one week intervals, rats were given single, increasing
doses of flutamide (25, 35, or 50 mg/kg) (Sigma Chemical Co., St.
Louis, Mo.). For each dose, flutamide was dissolved in peanut oil
and administered via i.p injection in a volume of 1 ml/kg. Rats
were tested with APO up to 48 hours at the intervals used for the
control series (determined in Study 1). Each dose of flutamide was
given 1 week after the previous dose, to allow APO-induced
erections to return to control levels.
[0157] Study 2b: Time Course of p,p-DDE Depression of APO Induced
Erections
[0158] One week after completion of the flutamide investigation,
rats were subjected to a control series of APO tests to determine
that erectile response had returned to baseline. From the group of
8 rats, 4 rats were randomly selected. These rats were subsequently
given 500 mg/kg p,p-DDE (prepared and administered as described in
Study 1). APO-induced erections and yawns were monitored for 2
weeks at APO-testing intervals of 0.5, 4, 12, 24, 48, 72 hours, 1
week, 2 weeks to determine the time course of p,p-DDE depression of
APO-induced erectile response.
[0159] Study 2c: Testosterone Supplementation
[0160] Two weeks after p,p-DDE administration, rats were given
testosterone supplementation in single doses (480 ug/kg, 1.2 or 2.4
mg/kg, i.p.) with each dose administered on a separate occasion.
The initial dose of 480 ug/kg was derived from the Heaton and
Varrin of testosterone supplementation of castrated rats (Heaton,
J. P. W. and Varrin, S. J.. J. Urol. 151:797(1994)). Testosterone
was administered in an attempt to recover APO-induced erections to
control levels.
[0161] For each dose of testosterone, APO-induced erections were
monitored over 12 hours at APO-testing intervals of 0.5, 4, 12
hours after testosterone administration. Each dose of testosterone
was given 48 hours after the previous dose. The required
testosterone concentrations were prepared using 100 mg/ml
testosterone propionate (Taro Pharmaceuticals, Bramalea, ON.)
diluted in peanut oil. Each dose was administered in a 1 ml/kg
volume. The remaining 4 rats from the initial group of 8 (not
treated with p,p-DDE) were used as controls for the p,p-DDE treated
rats. APO responses of the testosterone supplemented p,p-DDE
treated rats were compared to the APO responses of the 4 control
rats using a Student's unpaired t-test.
[0162] Statistical Analysis
[0163] For each APO testing protocol, the average number of
erections and standard deviation was determined. Prior to any
treatment, each rat underwent similar APO-testing intervals to
determine control APO-induced erections. Therefore, each rat served
as its own control. Treated values were compared to control values
using Student's paired t-test, except where noted in Study 2b.
Results
[0164] Study 1: p,p-DDE Administration
[0165] The 500 mg/kg dose showed a significant decrease in
apomorphine (APO)-induced erectile response 3 hours after p,p-DDE
administration. The 270 mg/kg dose of p,p-DDE had no significant
effect on APO-induced erections over the 5 hour testing period.
APO-induced yawning responses were not altered by the p,p-DDE
treatment (data not shown).
[0166] Study 2a: Flutamide Administration
[0167] The results from the dose-ranging study of flutamide on
APO-induced erections are presented in FIG. 22. A decrease in
APO-induced erections was found only at the highest dose of
flutamide at 0.5 and 4 hours after drug administration although
there appeared to be a trend at lower doses. Normal APO-induced
erectile responses were obtained at all doses 24 hours following
flutamide administration.
[0168] The 50 mg/kg dose of flutamide also caused a significant
decrease in the yawning response to APO at 4, 12 and 24 hours after
flutamide administration. In contrast, the 25 and 35 mg/kg doses of
flutamide did not effect APO-induced yawns.
[0169] Study 2b: Time Course of p,p-DDE Depression of APO Induced
Erections
[0170] Results from the time course assessment of p,p-DDE
suppression of APO-induced erections are shown in FIG. 23.
APO-induced erections were significantly decreased at 0.5, 4, 12,
24 hours and 2 weeks after administration of a single dose of 500
mg/kg p,p-DDE. FIG. 23 also compares the suppression of APO-induced
erections after 500 mg/kg p,p-DDE and 50 mg/kg flutamide.
APO-induced erections with flutamide administration returned to
control levels 48 hours after flutamide administration (n=4).
p,p-DDE persistently suppressed APO-induced erections over the two
week testing period. Two weeks after p,p-DDE administration,
APO-induced erections were significantly different from controls
and from the flutamide two week response.
[0171] APO-induced yawns over the two week assessment of p,p-DDE
were not significantly different from control levels.
[0172] Study 2c: Testosterone Supplementation
[0173] Two weeks after administration of 500 mg/kg p,p-DDE,
APO-erections remained significantly lower than controls.
Testosterone was administered to return APO-induced erections to
control levels. Results from testosterone supplementation on
APO-induced erections are shown in FIG. 24. For each dose of
testosterone, there were no significant increases in erections
compared to the levels of erections in p,p-DDE treated rats.
Similarly, compared to control levels, APO-induced erections with
all doses of testosterone remained significantly decreased at most
of the time points of APO testing.
[0174] Administration of p,p-DDE had little effect on APO-induced
yawns; subsequent administration of testosterone did not change the
status of yawning responses over the 12 hour test periods.
[0175] Discussion
[0176] The present study demonstrates that an environmental
chemical, such as p,p-DDE, can negatively impact vascular
condition, specifically, erectile function. Using the apomorphine
(APO) bioassay of erectile responses two specific findings were
that: (i) although both p,p-DDE and flutamide could decrease
erections acutely, p,p-DDE caused a persistent decrease in
APO-induced erectile function for longer than 2 weeks; and (ii)
administration of even high doses of testosterone beginning at 2
weeks after p,p-DDE administration failed to return APO-induced
erections to control levels.
[0177] The transient suppression of APO-induced erections by the
non-steroidal androgen receptor antagonist flutamide (i.e. the
return to control levels within 24 hours) is consistent with the
known pharmacokinetic and pharmacodynamic profile of this drug
(Berson, A., et al., J. Pharm. Exp. Ther. 265(l):366 (1993)). In
contrast, the persistent suppression of APO-induced erectile
response for more than two weeks following a single administration
of p,p-DDE, albeit a high dose, is in agreement with the known
persistence and bioaccumulating capacity of this environmental
contaminant. The dose of p,p-DDE which produced the erectolytic
effect was 10 fold greater than for flutamide. This is compatible
with the results in vitro involving androgen receptor binding
studies demonstrating that the affinity of p,p-DDE is 10 fold less
than flutamide (Kelce, W. R., et al., Nature. 375:581 (1995)).
Thus, the similar acute decrease in APO-induced erections with both
p,p-DDE and flutamide and the persistent of only the p,p-DDE effect
can be explained by the marked differences in clearance of the two
xenobiotics. Flutamide is rapidly metabolised by hepatic
cytochromes P450 in both rats and humans upon administration
(Berson, A., et al., J. Pharm. Exp. Ther. 265(1):366 (1993)). In
contrast, upon absorption p,p-DDE is not metabolised (Feldman, H.
A., et al., J. Urol. 151:54 (1994)) but rather incorporates into
adipose tissue and other lipid-containing tissues due to its
lipophilicity. Therefore, a single dose of p,p-DDE is retained in
body tissues over a long period of time (perhaps indefinitely)
whereas a single dose of flutamide is metabolised immediately after
administration and does not persist in the body.
[0178] The effects of p,p-DDE on plasma testosterone levels found
in the literature are somewhat inconclusive. The present results
involving the lack of effect of high dose testosterone
supplementation in rats previously treated with p,p-DDE do not
suggest an obvious mechanism. Interestingly, studies by Kelce et al
found that administration of p,p-DDE did not alter plasma
testosterone levels in pubertal or adults rats (Kelce, W. R., et
al., Nature. 375:581 (1995)), although the level of androgen
receptor antagonism was not determined. Our findings that even high
dose testosterone supplementation failed to return APO-induced
erections to previously treated p,p-DDE-rats potentially suggests
very prolonged receptor blockade but without involving `typical`
compensatory feedback upregulation of testosterone production.
[0179] The evidence suggesting that environmental contaminants can
contribute to erectile dysfunction represents a novel line of
epidemiological thinking. Current epidemiology surrounding
endocrine disrupters and reproduction in human beings has primarily
focussed on the potential effects of these contaminants on sperm
production and abnormalities in male and female reproductive system
development as well as increased incidences of hormone-dependent
cancers (Carlsen, E., et al., B.M.J 305(6854):609 (1992)). Although
these previous studies provide relevant background information,
they have, for the most part, overlooked the importance of vascular
condition (e.g., erectile function) as a critical component of
reproductive function.
[0180] In conclusion, the findings described herein support the
concept of the role of oxygen as an important regulator of gene
expression and cell phenotype, and thus, provide a scientific basis
for diagnosing vascular conditions associated with a reduction in
blood flow, hypoxic conditions and endothelial dysfunction.
[0181] While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
spirit and scope of the invention as defined by the appended
claims.
* * * * *